Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4h-quinazolin-3-yl)-benzonitrile and formulations thereof

Crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3-yl)-benzonitrile are developed to prevent aggregation and enhance stability in ophthalmic compositions, ensuring effective delivery to the ocular surface.

JP2024161426AInactive Publication Date: 2024-11-19BAUSCH & LOMB IRELAND LIMITED
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024128919
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2019-02-15
Filing Date
2024-08-05
Publication Date
2024-11-19
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Hydrophobic ophthalmic drugs tend to aggregate in aqueous topical compositions, leading to stability issues and quality problems due to drug-excipient interactions, making long-term therapy challenging.

Method used

Development of crystalline forms of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3-yl)-benzonitrile characterized by specific X-ray diffraction patterns, prepared through methods such as cooling, heating, or equilibration in solvents, to enhance stability and prevent aggregation.

Benefits of technology

The crystalline forms provide stable formulations that maintain drug efficacy, preventing aggregation and ensuring consistent delivery to the ocular surface, thereby addressing the stability and delivery challenges of hydrophobic ophthalmic drugs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161426000055
    Figure 2024161426000055
  • Figure 2024161426000056
    Figure 2024161426000056
  • Figure 2024161426000057
    Figure 2024161426000057
Patent Text Reader

Abstract

To provide a crystalline hydrate of 4-(7-hydroxy- 2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile, a method for preparing the crystalline hydrate, and pharmaceutical compositions comprising the crystalline hydrate.SOLUTION: There is provided a crystalline hydrate of 4-(7-hydroxy- 2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile, wherein the crystalline hydrate is characterized by an X ray diffraction pattern having three or more peaks at 2θ values selected from 6.6, 14.4, 18.3 ± 0.2° 2θ.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 806,697, which is hereby incorporated by reference in its entirety. No. 6,399,433, which is incorporated herein by reference in its entirety.

[0002] The present disclosure relates to 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline Crystalline forms of (3-yl)-benzonitrile (formula I), processes for their preparation and The present invention relates to formulations of Compound I and their use for treating ocular surface disorders. It also relates to methods for [Background technology]

[0003] Patients suffering from ocular surface pain, especially chronic ocular surface pain, experience a significant decrease in quality of life. Many suffer from depression, moderate to severe angina, dialysis, and disabling hip fractures. In many patients, ocular surface pain is not related to underlying pathology (e.g. Remains unresolved despite treatment for recent trauma or surgery, infection or inflammation No other known treatments are available for long-term therapy.

[0004] The transient receptor potential vanilloid 1 (TRPV1) receptor is involved in pain signaling. Antagonism of this receptor may be beneficial in pain conditions. Pain, especially chronic pain To alleviate this, it may be desirable to administer a formulation of a TRPV1 antagonist topically to the ocular surface. It would be interesting. Summary of the Invention [Problem to be solved by the invention]

[0005] Formulating hydrophobic ophthalmic drugs reduces their tendency to aggregate, especially within aqueous topical ophthalmic compositions. Aggregation can be particularly challenging due to the fact that it can affect stability and potentially other may pose quality issues and may be due to other interactions between the drug and excipients. Therefore, various polymorphs that may be incorporated into ocular formulations for delivery to the ocular surface are It is required to identify the morphology. [Means for solving the problem]

[0006] In some embodiments, the present invention provides a method for detecting the chromaticity of a chromaticity between 7.2, 12.7, and 21.4±0.2 degrees 2θ. The X-ray diffraction pattern is characterized by having three or more peaks at 2θ values ​​selected from the following: Structure [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 In some embodiments, the present invention relates to crystalline form A of (-yl)-benzonitrile (Compound I). , and the crystalline form A of compound I has the following average molecular weights: 7.2, 12.7, 13.9, 18.1, 21.4, and 25. X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 1 and 26.8±0.2°2θ In some embodiments, the present disclosure provides a method for preparing a compound I. A method for preparing crystalline form A comprises cooling a hot solution of the free base of Compound I in methanol. and cooling to about 0° C. to crystallize Compound I as crystalline form A. Regarding the law.

[0007] In some embodiments, the present invention provides a method for detecting a concentration of 1000 ppm or less from 7.4, 14.9, 19.1 ± 0.2 degrees 2θ. Characterized by an X-ray diffraction pattern with three or more peaks at selected 2θ values ,structure [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 In some embodiments, the present invention relates to crystalline form C of (-yl)-benzonitrile (Compound I). , and the crystalline form C of compound I has the following average molecular weights: 7.4, 14.1, 14.9, 16.4, 19.1, 26. X-ray diffraction with three or more peaks at 2θ values ​​selected from 1, 31.2±0.2°2θ In some embodiments, the present invention provides a crystal of Compound I. A method for preparing Form C, comprising: heating Compound I in crystalline Form A at at least about 250° C. or to a temperature of at least about 270° C., or to about 280° C. .

[0008] In some embodiments, the present invention provides a method for detecting a concentration of 12.7, 16.7, 22.6±0.2 degrees 2θ. The X-ray diffraction pattern is characterized by having three or more peaks at 2θ values ​​selected from the following: Structure [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 In some embodiments, the present invention relates to crystalline form E of (-yl)-benzonitrile (Compound I). , and the crystal form E of compound I is 12.7, 15.1, 16.7, 22.6, 27.1, 27 X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 28.5±0.2°2θ and 28.5±0.2°2θ. In some embodiments, the present invention provides a method for preparing a granular polymer comprising the steps of: A method for preparing crystalline form E, comprising the steps of: heating a hydrate form of compound I at about 250° C. or about 260° C. and heating the compound I to a temperature higher than 100° C. to provide compound I as crystalline form E. .

[0009] In some embodiments, the present invention provides a method for producing a compound comprising the steps of: [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 This relates to the crystalline hydrate of (-yl)-benzonitrile (Compound I).

[0010] In some embodiments, the crystalline hydrate of Compound I has a molecular weight of 6.6, 14.4, 18.3±0. .2°2θ by an X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from In some embodiments, the crystalline hydrate of Compound I is characterized by an average molecular weight of 6.6, 11.9, 12.0, 13.0, 14.0, 15.0, 16.0, 17.0, 18.0, 19.0, 20.0, 21.0, 22.0, 23.0, 24.0, 25.0, 26.0, 27.0, , 14.4, 18.3, 23.9, 26.5, 29.2 ± 0.2 ° 2θ selected from It is characterized by an X-ray diffraction pattern with three or more peaks at θ values. In an embodiment, the present invention provides a method for preparing a crystalline hydrate of Compound I, comprising the steps of: Equilibrating a slurry of compound I in a mixture with a solvent to crystallize compound I as a crystalline hydrate In some embodiments, the water-miscible solvent is acetone. In some embodiments, the equilibration is for about 12 hours, about 18 hours, or about 24 hours. or over a period of approximately 48 hours.

[0011] In some embodiments, the present invention provides a method for producing a compound comprising the steps of: [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 This relates to a crystalline methanol solvate of (-yl)-benzonitrile (Compound I).

[0012] In some embodiments, the crystalline methanol solvate of Compound I has a pH of 6.1, 14.5 , 22.7±0.2°2θ, or 3 or more peaks at 2θ values ​​selected from In some embodiments, the crystalline methanol solution of Compound I is characterized by a turn. The solvates were 6.1, 12.2, 14.5, 18.0, 22.7, and 24.6 ± 0.2 °2 Characterized by an X-ray diffraction pattern with three or more peaks at 2θ values ​​selected from θ In some embodiments, the present invention provides a crystalline methanol solvate of Compound I. The method for preparing the polymorphic form of Compound I comprises equilibrating a slurry of Compound I in methanol. and obtaining compound I as a crystalline methanol solvate. In some embodiments, equilibration is carried out at room temperature for at least about 24 hours. It will be carried out.

[0013] In some embodiments, the present invention provides a method for producing a compound comprising the steps of: [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 Regarding the crystalline acetonitrile solvate (form J) of (-yl)-benzonitrile (compound I) do.

[0014] In some embodiments, the crystalline acetonitrile solvate of compound I has a pH of 8.2, 17 X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 23.8±0.2°2θ, 23.0±0.2°2θ In some embodiments, the crystalline acetone of Compound I is characterized by a folding pattern. Nitrile solvates: 8.2, 11.8, 17.0, 22.8, 23.8, 27.6±0 .2°2θ by an X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from In some embodiments, the present invention provides a crystalline acetonitrile preparation of Compound I. A method for preparing a solvate comprising equilibrating a slurry of Compound I in acetonitrile. and providing Compound I as a crystalline acetonitrile solvate. In some embodiments, equilibration is carried out at room temperature for at least about 24 hours.

[0015] In some embodiments, the present invention provides a method for detecting a concentration of 5.3, 12.3, 22.4±0.2 degrees 2θ. Characterized by an X-ray diffraction pattern with three or more peaks at selected 2θ values ,structure [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 In some embodiments, the present invention relates to crystalline form K of (-yl)-benzonitrile (Compound I). , and the crystal form K of compound I is 5.3, 6.5, 10.5, 12.3, 17.2, 19.3 , 22.4±0.2°2θ, or 3 or more peaks at 2θ values ​​selected from In some embodiments, the present invention provides a crystalline form of Compound I. A method for preparing form K, comprising crystallizing the compound I by evaporation of a solution of the compound I in acetone, providing compound I in crystalline form K.

[0016] In some embodiments, the present invention provides a method for determining the concentration of a saturation factor selected from 7.1, 8.7, 10.6±0.2 degrees 2θ. characterized by an X-ray diffraction pattern having three or more peaks at selected 2θ values, structure [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 In some embodiments, the present invention relates to crystalline form L of (-yl)-benzonitrile (Compound I). , and the crystal form L of compound I is 3.5, 7.1, 8.7, 10.6, 12.2, 19.1, An X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 22.4±0.2°2θ In some embodiments, the present invention provides a crystalline form of Compound I. A method for preparing compound L comprises adding a hydrocarbon solvent to a solution of compound I in acetone to form compound L. In some embodiments, the method comprises providing compound I in crystalline form L. The hydrochloric acid solvent is hexane.

[0017] In some embodiments, the present disclosure provides an effective amount of crystalline form A, crystalline form C, crystalline form D, , crystalline form E, crystalline form F, crystalline form L, crystalline form K, and combinations thereof. and a crystalline form of Compound I according to any of the crystalline forms described above, and a pharma- ceutically acceptable excipient. The present invention provides a pharmaceutical formulation comprising:

[0018] In some embodiments, the present disclosure provides a method for the preparation of a crystalline form comprising administering to a patient a crystalline form comprising administering to said ... C, crystalline form D, crystalline form E, crystalline form F, crystalline form L, crystalline form K, and combinations thereof and a pharma- ceutically acceptable excipient, Pharmaceutical formulations for ocular use (eg, topical application to the ocular surface) are provided.

[0019] In some embodiments, the present disclosure provides a pharmaceutical formulation comprising crystalline Form A in substantially pure form. to provide.

[0020] In some embodiments, the present disclosure provides a pharmaceutical formulation comprising crystalline Form C in substantially pure form. to provide.

[0021] In some embodiments, the present disclosure provides a pharmaceutical formulation comprising crystalline form E in substantially pure form. to provide.

[0022] In some embodiments, the present disclosure provides a pharmaceutical formulation comprising crystalline form F in substantially pure form. to provide.

[0023] In some embodiments, the present disclosure provides a pharmaceutical formulation comprising crystalline form K in substantially pure form. to provide.

[0024] In some embodiments, the present disclosure provides a pharmaceutical formulation comprising crystalline form L in substantially pure form. to provide.

[0025] In some embodiments, the present disclosure provides pharmaceutical compositions comprising a mixture of two or more crystalline forms of Compound I. A pharmaceutical formulation is provided.

[0026] In some embodiments, the present disclosure provides crystalline forms B and E, crystalline forms B and F, crystalline forms A mixture of crystal forms B and C, crystal forms A and C, and crystal forms A and F in a ratio of about 1:99 to about 99:1. A pharmaceutical formulation comprising the compound is provided.

[0027] In some embodiments, a pharmaceutical formulation comprising any of the crystalline forms disclosed herein is , formulated for ophthalmic use (eg, topical application to the ocular surface).

[0028] In some embodiments, provided herein is an aqueous formulation comprising: 4-(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl) -benzonitrile (compound I) or a salt, co-crystal or polymorph thereof, and A surfactant, a suspending agent, an osmotic agent, a buffer, a preservative, a salt, and a preservative are selected from the group consisting of The present invention relates to an aqueous formulation comprising one or more excipients.

[0029] In some embodiments, 4-(7-hydroxy-2-isopropyl-4-oxo-4 H-quinazolin-3-yl)-benzonitrile (Compound I) or its salt, cocrystal or The polymorph is present as a suspension in the formulation. In alternative or additional embodiments, the 4-( 7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzoate Zonitrile (Compound I) or a salt, cocrystal, or polymorph thereof may be present in a concentration of from about 0.5% w / v to about 3 Present in the formulation in an amount of .5% w / v.

[0030] In some embodiments, the present disclosure provides: 4-, which is present as a suspension in the formulation in an amount of about 0.5% w / v to about 3.5% w / v. (7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-be benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof; Surfactants, Suspension agents, and one or more excipients selected from the group consisting of osmotic agents, buffers, preservatives, salts and preservatives; An aqueous formulation comprising:

[0031] In some embodiments, the invention described herein comprises: 4-(7-hydroxy-2-isopropyl) (4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or a suspension of a salt, co-crystal or polymorph of Non-ionic surfactants; Suspension agents; Osmotic agents; buffer; Salt; and The formulation optionally contains a preservative.

[0032] In some embodiments, the present disclosure provides: 4-(7-hydroxy-2-isopropyl) (4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or a suspension of a salt, co-crystal or polymorph of Selected from the group consisting of nonionic, anionic, cationic surfactants and combinations thereof. surfactants; Suspension agents; Osmotic agents; buffer; Optionally salt; Optionally, a preservative; and For formulations containing qs water up to 100%.

[0033] In some embodiments, the formulation comprises a non-ionic surfactant. In some embodiments of the formulation, the non-ionic surfactant is a polysorbate surfactant. , block copolymers of ethylene oxide, propylene oxide surfactants, poloxamers , tyloxapol, and combinations thereof.

[0034] In some embodiments of the formulations described herein, the non-ionic surfactant is at least At least about 0.001% w / v, at least about 0.01% w / v, at least about 0.02% at least about 0.03% w / v or at least about 0.04% w / v; and About 1% w / v or less, about 0.5% w / v or less, about 0.3% w / v or less, or about 0.2% w / v Tyloxalate present in an amount of about 0.1% w / v or less, or about 0.08% w / v or less In some embodiments, tyloxapol is about 0.03% w / v to 0. 0.08% w / v or about 0.05% w / v.

[0035] In some embodiments of the formulations described herein, a non-ionic surfactant is present in the formulation. The poloxamer is in an amount of about 15% w / v to about 20% w / v.

[0036] In some embodiments of the formulations described herein, the suspending agent is a carbomer, hydrochloride, Hypromellose, polyethylene glycol and its combinations In some embodiments, the suspending agent is selected from the group consisting of at least about 0. 0.05% w / v, at least about 0.1% w / v, or at least about 0.2% w / v, and in an amount of about 1.0% w / v or less, about 0.6% w / v or less, or about 0.5% w / v or less Carbomer present in the formulation. In some embodiments, the carbomer is 0.1% It is present in the formulation in an amount of from about 0.3% w / v to about 0.2% w / v.

[0037] In some embodiments of the formulations described herein, the suspending agent has a viscosity of at least about 0.05%. 5% w / v, at least about 0.1% w / v, or at least about 0.25% w / v, and less than about 1.8% w / v, less than about 1.0% w / v, less than about 0.8% w / v, or less than about 0.6% Hydroxypropyl methylcellulose present in the formulation in less than w / v amounts. In some embodiments, the suspending agent has a molecular weight of about 200 Da to about 20,000 Da. In some embodiments, the suspending agent is polyethylene glycol (PEG). %w / v to about 9%w / v, about 5%w / v to about 8%w / v, or about 7%w / v EG400 or about 1% w / v to about 4% w / v, about 1% w / v to about 3% w / v, or about 2 % w / v concentration of PEG 6000.

[0038] In some embodiments of the formulations described herein, the suspension contains substantially all of the cal It is a Bomer homopolymer type B.

[0039] In some embodiments of the formulations described herein, the osmotic agent comprises a polyol. The compound is selected from the group consisting of:

[0040] In some embodiments of the formulations described herein, the polyol is mannitol, Glycerin, xylitol, sorbitol and propylene glycol and combinations thereof In some embodiments, the polyol is selected from the group selected from about 0.05% w / v ~ approx. 10% w / v, approx. 0.1% w / v ~ approx. 8% w / v, approx. 0.1% w / v ~ approx. 7% In certain embodiments, the compound is present in an amount of about 0.1% w / v to about 5% w / v. The polyol is 0.1% w / v to about 5% w / v, or about 0.2% w / v, about 0.3% w / v , approx. 0.4%w / v, approx. 0.5%w / v, approx. 1%w / v, approx. 2%w / v, approx. 2.5%w / v, about 3.0% w / v, about 3.5% w / v, about 4.0% w / v, about 4.5% w / v or about Mannitol or glycerin, present in the formulation in an amount of 5% w / v.

[0041] In some embodiments of the formulations described herein, the buffer is selected from the group consisting of acetate, ascorbic acid, and the like. Phosphate, borate, bicarbonate, carbonate, citrate, edetate (EDTA) gluconate from the group consisting of salts, lactates, phosphates, propionates and TRIS (tromethamine) In certain embodiments, the buffer is phosphate or TRIS.

[0042] In some embodiments of the formulations described herein, the salt is sodium chloride or chloride. It is potassium.

[0043] In some embodiments of the formulations described herein, the suspending agent is carbopol (Carbopol). The amount of sodium chloride is about 60r at 25°C. When using spindle CP-42 at pm, the viscosity of the formulation is about 20 cP to about 200 cP. In some embodiments, the sodium chloride is adjusted to about 0.01% w / v ~ approx. 0.5%w / v, approx. 0.02%w / v ~ approx. 0.4%w / v, approx. 0.03%w / v ~0.3%w / v, approx.0.04%w / v~0.2%w / v, approx.0.05%w / v~approx. It is present in an amount of 0.1% w / v or about 0.05% w / v.

[0044] In some embodiments of the formulations described herein, the pH of the formulation is from about 5.5 to about 8. In some embodiments, the pH of the formulation is about 6.0 to about 8.0, about 6.0 or is approximately 7.4.

[0045] In some embodiments, the formulations described herein comprise at least about 1.5% w / v , at least about 3.0 w / v%, at least about 3.5 w / v%, or at least about 4.5 w / v% / v%, but not more than about 10.0 w / v%, not more than about 8.0 w / v%, not more than about 6.5 w / v% Cyclodextrin in an amount of about 5.5 w / v% or less In some embodiments, the cyclodextrin comprises about 5% of the formulation. Hydroxypropyl β-cyclodextrin or sulfoalkyl ether in an amount of % w / v It is ether β-cyclodextrin.

[0046] In some embodiments, the present disclosure provides: Compound I or a salt, cocrystal or polycrystal thereof in an amount of about 0.5% w / v to about 2.5% w / v shape, Tyloxapol, poloxamer or similar in an amount of about 0.01% w / v to 0.2% w / v A nonionic surfactant which is a combination of Hydroxypropyl methylcellulose, polyethylene glycol or carbomer homopoly A suspension that is of the mer B type; At least one polyol in an amount of about 0.05% w / v to about 10% w / v. Osmotic agents; Buffers that are edetate, phosphate, borate, or combinations thereof Salt; and Contains up to 100% qs water; and The pH of the formulation ranges from about 5.5 to about 8.0.

[0047] In some embodiments, the present disclosure provides: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. Compound I or a salt, co-crystal or polymorph thereof, present in an amount of 5% w / v; Tyloxapol in an amount of about 0.04% w / v to about 0.06% w / v, about 0.005% A non-ionic boundary layer that is a poloxamer or a combination thereof in an amount of 0.12% w / v to 0.2% w / v. Surfactants; Hydroxypropyl methylcellulose in an amount of about 0.1% w / v to about 0.8% w / v , polyethylene glycol in an amount of about 2% w / v to about 8% w / v, about 0.05% w / v Carbomer homopolymer type B or combinations thereof in an amount of about 0.5% w / v to about 0.5% w / v. Clouding agent; Osmolality is mannitol or glycerin in an amount of about 0.1% w / v to about 5% w / v. Agent; a buffer which is edetate, phosphate, borate, tromethamine or a combination thereof; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; and Contains up to 100% qs water; and The formulation has a pH in the range of about 5.5 to about 8.0.

[0048] In some embodiments, the present disclosure provides: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. 4-(7-hydroxy-2-isopropyl-4-oxo-4H- Quinazoline-3-yl)-benzonitrile (Compound I) or its salts, co-crystals or polymorphs Suspension of the body, Tyloxapol in an amount of about 0.04% w / v to about 0.06% w / v; Carbomer homopolymer type B in an amount of about 0.05% w / v to about 0.4% w / v; glycerin in an amount of about 0.5% w / v to about 5% w / v; Selected from the group consisting of edetate, phosphate, borate, tromethamine and combinations thereof. buffer solutions; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; and A formulation containing up to 100% qs water, The formulation has a pH in the range of about 5.5 to about 8.0.

[0049] In some embodiments of the formulations described herein, Compound I is polymorphic Form B. .

[0050] In some embodiments, the present disclosure provides: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. 4-(7-hydroxy-2-isopropyl-4-oxo-4H- A suspension of polymorphic form B of quinazolin-3-yl)-benzonitrile (Compound I); Tyloxapol in an amount of about 0.04% w / v to about 0.06% w / v; Carbomer homopolymer type B in an amount of about 0.05% w / v to about 0.4% w / v; glycerin in an amount of about 0.5% w / v to about 5% w / v; a buffer selected from edetate, phosphate, borate, tromethamine or combinations thereof; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; and A formulation containing up to 100% qs water, The formulation has a pH in the range of about 5.5 to about 8.0.

[0051] In some embodiments, the formulation comprises: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. Compound I in an amount of 5% w / v, about 0.05% w / v tyloxapol; Carbomer homopolymer type B at approximately 0.2% w / v; glycerin at about 2.0% w / v; Tromethamine buffer; and Hydrochloric acid to adjust the pH to about 6.4 to about 8.4; About 0.05% w / v sodium chloride; and Contains up to 100% qs water, Contains no preservatives.

[0052] In some embodiments of the formulations described herein, polymorphic Form B of Compound I is 9. Three or more peaks at 2θ values ​​selected from 3, 10.6 and 14.4±0.2°2θ It is characterized by an X-ray diffraction pattern having

[0053] In some embodiments, the formulations described herein have a glycerol content of about 20 cP to about 200 cP. It has viscosity.

[0054] In some embodiments, the formulations described herein contain from about 200 to about 450 mg / kg of It has an osmolality of milliosmoles per gram (mOsm / kg).

[0055] In some embodiments of the formulations described herein, the D 90 (Compound I The diameter (90% of which is made up of smaller particles) is less than about 10 μm, less than about 8 μm, and less than about 6 μm. In some embodiments, the compound is less than about 1 μm, less than about 4 μm, less than about 3 μm, or less than about 2 μm. D of compound I in the preparation 50 (the diameter at which 50% of compound I is made up of smaller particles) is approximately Less than 10 μm, Less than about 8 μm, Less than about 6 μm, Less than about 4 μm, Less than about 3 μm, Less than about 2 μm In some embodiments, the D of Compound I in the formulation is less than or about 1 μm. 10 (Compound I The diameter of the particles (10% of which are smaller than the diameter of the particles) is less than about 5 μm, less than about 4 μm, and less than about 3 μm. m, less than about 2 μm, less than about 1 μm, or about 0.3 μm.

[0056] In some embodiments of the formulations described herein, the formulations have a shelf life of 6 months at room temperature. After piping, less than about 10%, less than about 8%, less than about 7%, less than about 6%, less than about 5%, less than about 4%, Exhibits less than about 3% or less than about 2% precipitation.

[0057] In some embodiments of the formulations described herein, the amount of Compound I in the formulation is refrigerated. After about 6 months, about 8 months, about 10 months, about 12 months, about 15 months or At least 90% of the original amount after about 18 months.

[0058] In some embodiments of the formulations described herein, the amount of Compound I in the formulation is refrigerated. At least about 91% and at least about 92% of the original amount after about 18 months of storage under , at least about 93%, at least about 94%, at least about 95%, at least 96%, At least about 97% or at least about 98%.

[0059] In some embodiments of the formulations described herein, the formulations remain stable after six months under refrigeration. The degradation products were approximately 10% or less in the presence of 0.1% trifluoroacetic acid (TFA ) when analyzed by HPMC using a gradient of water / acetonitrile mobile phase, the compound I has a relative retention time of 1.23.

[0060] In some embodiments of the formulations described herein, about 10% or less of Compound I in the formulation The lower one decomposes when stored at 40°C for 12 weeks.

[0061] In some embodiments of the formulations described herein, Compound I is present in crystalline form A, crystalline form B, B, crystal form C, crystal form E, crystal form F, crystal form G, crystal form J, crystal form K, crystal It is a crystalline form selected from the group consisting of form L and combinations thereof.

[0062] In some embodiments of the formulations described herein, Compound I is present in crystalline form A, crystalline form B, B, crystalline form C, crystalline form E, crystalline form F, crystalline form K, crystalline form L, and combinations thereof The crystalline form is selected from the group consisting of:

[0063] In some embodiments, the present disclosure provides: A quantity of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 -yl)-benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof; Non-ionic surfactants; Suspension agents; Osmotic agents; buffer; salt; Optionally, a preservative; and Mix with water up to 100% qs; and The present invention relates to a method of preparing the formulation, comprising adjusting the pH to a range of about 5.5 to about 8.0.

[0064] In some embodiments, the method of making the formulations disclosed herein comprises preparing a stock suspension and In some embodiments, the stock suspension comprises the addition of Compound I to obtain a desired particle size. In some embodiments, the D of compound I in the formulation is 90 ( The diameter (in which 90% of Compound I is made up of smaller particles) is less than about 10 μm, less than about 8 μm In some embodiments, the thickness is less than about 6 μm, less than about 4 μm, less than about 3 μm, or about 2 μm. In this embodiment, the D 50 (50% of compound I is composed of smaller particles. diameter) is less than about 10 μm, less than about 8 μm, less than about 6 μm, less than about 4 μm, less than about 3 μm, In some embodiments, the D of Compound I in the formulation is less than about 2 μm or about 1 μm. 10 (diameter of particles smaller than 10% of Compound I) is less than about 5 μm, less than about 4 μm less than about 3 μm, less than about 2 μm, less than about 1 μm, or about 0.3 μm.

[0065] In some embodiments, the present disclosure provides for the treatment of ocular surface pain in a subject in need thereof. The method comprises administering to a subject a subject of the present invention a method for treating a subject of the present invention, comprising administering to a subject a subject of the present invention a method for treating a subject of the present invention ... [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 -yl)-benzonitrile (compound of formula I) or a salt, solvate, polymorph or conjugate thereof The method includes administering a compound according to the invention to a subject.

[0066] In some embodiments, the ocular surface pain is acute or episodic ocular surface pain. In some embodiments, the ocular surface pain is relieved for at least 1 month, at least 2 months, or at least In some embodiments, the compound of formula I is a compound of formula I. The composition is administered to the cornea of ​​a subject.

[0067] In some embodiments, the COSP is associated with dry eye disease. In embodiments, administration results in a reduction in symptoms of dry eye disease. In some embodiments, administration results in a reduction in pain associated with dry eye disease. Symptoms include dry eyes, eye discomfort, bloodshot eyes, burning or stinging in the eyes, roughness or foreign body sensation. The present invention provides a reduced incidence of at least about 10% in one or more of the following: irritability, dizziness, or photophobia.

[0068] In some embodiments, the subject is diagnosed with dry eye disease, Sjogren's syndrome, conjunctivitis (keratitis), or the like. conjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), corneal epithelial basement membrane dystrophy, Acanthamoeba, fibromyalgia, meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, circles Keratoconus, Ocular pain syndrome, Stevens-Johnson syndrome, Corneal epitheliopathy, Corneal neuropathy corneal dystrophy (including LASIK-induced corneal neuropathy), corneal dystrophy (recurrent corneal dystrophy) corneal erosion or abrasion (including recurrent corneal keratoconjunctivitis), epithelial basement membrane dystrophy, (including corneal erosion or corneal abrasion), ocular surface disease, blepharitis, graft-versus-host disease, myocardial infarction, Conjunctivitis, glaucoma, conjunctival laxity, keratopathy (herpetic keratopathy, filamentous keratopathy, band-shaped or bullous keratopathy) Keratopathy, including lagophthalmos, keratitis (including herpes simplex virus keratitis), iritis , episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, nerve Patients recovering from nutritional keratitis or undergoing photorefractive keratectomy (PRK) surgery or persisted for at least 3 months after laser in situ keratomileusis (LASIK) surgery suffer from one or more of the eye pain conditions listed above.

[0069] In some embodiments, the methods include administering an additional therapeutic agent to the subject.

[0070] In some embodiments, administration is at least about 3 to at least about 10% compared to placebo. about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least resulting in a reduction in pain score on the visual acuity scale (VAS) of about 9 or at least about 10. In some embodiments, the reduction in VAS score is measured before and after administration of Compound I to the subject. The method according to claims 101 to 102 is based on the difference in VAS scores. The reduction in core may occur within about half an hour, about one hour, about two hours, or about one hour after administration of Compound I to a subject. Occurs within 4 hours or from about 2 to 4 hours.

[0071] In some embodiments, administration of Compound I results in a response rate of 1: At least about 1, at least about 2, at least about 3, at least about 4, or at least about 5 resulting in a reduction in hyperemia in the subject.

[0072] In some embodiments, administration reduces best corrected visual acuity, intraocular pressure, slits, and the like compared to placebo. Changes in one or more of the following: light biomicroscopy, dilated pupils, blink rate, tear production, and corneal staining. does not result in transformation.

[0073] In some embodiments, the compound of formula I is in the form of a formulation described herein. In some embodiments, the formulation is administered for at least about 1, about 2, or about 3 months. In some embodiments, the formulation is administered 1 to 4 times daily.

[0074] In some embodiments, the present disclosure provides a method for treating ocular surface pain comprising administering to a subject the method of the present disclosure a therapeutically effective amount of the compound described herein. In some embodiments of the above uses, the ocular surface pain is treated by Paroxysmal (e.g., The pain may be acute (e.g., acute) ocular surface pain or chronic ocular surface pain.

[0075] In some embodiments, the present disclosure provides a method for reducing ocular surface pain in a subject in need thereof. 16. A method for producing a composition comprising the steps of: [ka] 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 -yl)-benzonitrile (formula I) or a salt, solvate, polymorph or co-crystal thereof The method includes administering an eye drop to the patient.

[0076] In some embodiments, the ocular surface pain is paroxysmal (e.g., acute) ocular surface pain; The ocular surface pain is chronic ocular surface pain (COSP). In some embodiments, COSP is associated with dry eye disease.

[0077] In some embodiments, administration results in a reduction in symptoms of dry eye disease.

[0078] In some embodiments, administration results in a reduction in pain associated with dry eye disease. In some embodiments, administration may be associated with symptoms such as dry eye, eye discomfort, eye redness, eye burning or stinging. At least about 10% reduction in one or more of the symptoms of skin roughness, roughness or foreign body sensation, or photophobia. Resulting in a survival rate.

[0079] In some embodiments, the subject is diagnosed with dry eye disease, Sjogren's syndrome, conjunctivitis (keratitis), or the like. conjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), corneal epithelial basement membrane dystrophy, Acanthamoeba, fibromyalgia, meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, circles Keratoconus, Ocular pain syndrome, Stevens-Johnson syndrome, Corneal epitheliopathy, Corneal neuropathy corneal dystrophy (including LASIK-induced corneal neuropathy), corneal dystrophy (recurrent corneal dystrophy) corneal erosion or abrasion (including recurrent corneal keratoconjunctivitis), epithelial basement membrane dystrophy, (including corneal erosion or corneal abrasion), ocular surface disease, blepharitis, graft-versus-host disease, myocardial infarction, Conjunctivitis, glaucoma, conjunctival laxity, keratopathy (herpetic keratopathy, filamentous keratopathy, band-shaped or bullous keratopathy) Keratopathy, including lagophthalmos, keratitis (including herpes simplex virus keratitis), iritis , episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia or glaucoma In some embodiments, the patient is suffering from one or more of the following: The subjects were those who had undergone photorefractive keratectomy (PRK) or laser ablation (LA) surgery. Patients who have had persistent eye pain for at least 3 months after SIK surgery. In some embodiments, the methods include administering an additional therapeutic agent to the subject.

[0080] In some embodiments, administration is at least about 3 to at least about 10% compared to placebo. about 4, at least about 5, at least about 6, at least about 7, at least about 8, at least resulting in a reduction in pain score on the visual acuity scale (VAS) of about 9 or at least about 10. In some embodiments, administration is at least about 6, at least about 10, or at least about 20% greater than placebo. A reduction in VAS pain score of about 7, at least about 8, at least about 9, or at least about 10. In some embodiments, the reduction in pain score is achieved prior to administration of Compound I to the subject. In another embodiment, the reduction in pain score is due to the difference in pain scores after administration of Compound I. In some embodiments, the reduction in pain score occurs about 7 days after administration of the compound to the subject. This occurs approximately 14 days after administration of Compound I to the subject.

[0081] In some embodiments, administration comprises administering at least In about 1, at least about 2, at least about 3, at least about 4, or at least about 5 subjects This results in a reduction in congestion.

[0082] In some embodiments, administration results in a decrease in the VAS score compared to before administration of the compound. Both results in a reduction in pain score on the visual analog scale (VAS) of approximately 3.

[0083] In some embodiments of the recited methods, the compound of formula I is, as described herein, It is administered in the form of a formulation.

[0084] In some embodiments, the present disclosure provides for the treatment or reduction of ocular surface pain in a subject in need thereof. 1. A method for performing on a subject, comprising the structure: [ka] The compound 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolidinyl A method for the treatment of a patient comprising administering to a subject a formulation containing (benzoyl)-3-yl-benzonitrile (Compound I). Regarding the law: The formulations resulted in a Cmax of Compound I in the rabbit cornea that was approximately 1.5 to approximately 3 times the Cmax in the conjunctiva. , Cmax is the maximum concentration of Compound I in a particular tissue after administration of a single dose. In some embodiments, Compound I is administered in a formulation described herein.

[0085] In some embodiments, the present disclosure provides for the treatment or reduction of ocular surface pain in a subject in need thereof. 1. A method for performing on a subject, comprising the structure: [ka] The compound 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolidinyl A method for the treatment of a patient comprising administering to a subject a formulation containing (benzoyl)-3-yl-benzonitrile (Compound I). Regarding the method, the formulation showed a Cmax of Compound I in rabbit corneas that was approximately 500 times that of Compound I in plasma. Cmax of Compound I is determined by the chemical conversion in a particular tissue after administration of a single dose. In some embodiments, compound I is a maximal concentration of It is administered as a formulation.

[0086] Particular preferred embodiments of the present invention are described in the following specific preferred embodiments and claims. This will become apparent from the more detailed description below. [Brief description of the drawings]

[0087] [Figure 1] 1 provides an overlay of experimental and calculated XRPD patterns of crystalline Form A of Compound I. [Diagram 2] 1 provides an X-ray powder diffraction pattern of crystalline Form A of Compound I. [Diagram 3] 1 provides an overlay of experimental and calculated XRPD patterns of crystalline Form C of Compound I. [Figure 4] 1 provides an X-ray powder diffraction pattern of crystalline Form C of Compound I. [Diagram 5] 1 provides an overlay of experimental and calculated XRPD patterns of crystalline form E of compound I. [Figure 6] 1 provides an X-ray powder diffraction pattern of crystalline form E of Compound I. [Figure 7] 1 provides an X-ray powder diffraction pattern of crystalline form F of Compound I (hydrate HA). [Figure 8] 1 provides an overlay of experimental and calculated XRPD patterns of crystalline form G of compound I (methanol solvate SB). [Figure 9] 1 provides an X-ray powder diffraction pattern of crystalline form G of Compound I (methanol solvate SB). [Figure 10] 1 provides an X-ray powder diffraction pattern of crystalline form J of Compound I (acetonitrile solvate SA). [Figure 11] 1 provides an X-ray powder diffraction pattern of crystalline form K of Compound I. [Figure 12] 1 provides an X-ray powder diffraction pattern of crystalline form L of compound I. [Figure 13]1 illustrates the relationship between polymorphic and solvated / hydrated forms of the free base of Compound I and exemplary methods for their conversion. [Figure 14A] Figure 14A shows the percent of Compound I in the exploratory formulations described in Table 13 over 12 weeks at room temperature. In Figure 14A, the formulations with a percent of Compound I of about 75% of the original at 12 weeks are formulations of Compound I as a solution. [Figure 14B] Figure 14B shows the percent of Compound I in the exploratory formulations after 12 weeks at 40° C. In Figure 1B, the formulations with a percent of Compound I of about 20% of the original at 12 weeks are formulations of Compound I as a solution. [Figure 15] 1 shows powder X-ray diffraction patterns of Compound I recovered from 12 week stability samples versus controls. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0088] The TRPV1 receptor is a transient receptor that has been characterized by molecular cloning and pharmacology. This refers to receptor potential vanilloid 1. For example, Caterina MJ, et al.,. See Nature 1997;389:816-824. The properties are described in WO 2005 / 120510, which is hereby incorporated by reference in its entirety. The measurements are taken as described in the brochure No.

[0089] The term "effective amount" of a compound described herein is an amount that allows the compound to perform its intended function in a mammal. An effective amount of a therapeutic compound refers to the amount of a therapeutic compound that is necessary or sufficient to cause a therapeutic effect in a mammal. The amount of causative agent already present in the mammal, the age, sex and weight of the mammal and the ocular Depending on factors such as the ability of the therapeutic compounds of the present disclosure to treat a surface disorder and / or its symptoms, Therefore, it may vary.

[0090] The phrase "ophthalmologically compatible" means that excessive toxicity is avoided in response to a reasonable benefit / risk ratio. - The ocular tissue of humans and animals can be treated without toxicity, irritation, allergic reactions or other problems or complications. Refers to formulations, polymers and other materials and / or dosage forms that are suitable for use in contact with .

[0091] As used herein, the terms "treat" and "treat" in relation to a disease or disorder are used interchangeably. "Treatment" or "treatment" refers, in some embodiments, to improving a disease or disorder. That is, to slow or prevent the development of the disease or at least one of its clinical symptoms, In another embodiment, "treatment" refers to "reducing" or "treating." " is defined as a measurement of at least one physical parameter, including those that may not be discernible by the patient. In yet another embodiment, "treat" or "treat" refers to reducing or ameliorating the "Treatment" or "treatment" refers to any effect that is physical (e.g., stabilization of discernible symptoms), physiological (e.g., modulating the disease or disorder by either or both of the following: In yet another embodiment, "treat", "treating" or "treatment" refers to the treatment of a disease. refers to preventing or delaying the onset, development or progression of a disease or disorder or its symptoms vinegar.

[0092] As used herein, the term "subject" or "patient" refers to humans, as well as primates, rabbits, Non-human mammals, including but not limited to pigs, horses, dogs, cats, sheep and cows. In certain embodiments, the subject or patient is a human. The term "patient" or "subject" refers to a person suffering from a condition (i.e., a disease or disorder) as described herein. As used herein, refers to a person who is suffering from and who would benefit from treatment. The objective is to ensure that such subjects (patients) do not suffer any biological, medical or life-threatening effects from such treatment. A subject is "in need of" treatment if he or she will benefit in quality of life. In certain embodiments, a subject is in need of at least In some embodiments, the subject is an adult human at least about 18 years of age. In some embodiments, the subject is a child about 18 years of age or younger. .

[0093] As used herein, "ocular surface" refers to the anatomical portion of the cornea (epithelium, Bowman's layer, corneal lamina propria, etc.). The outer surface of the eye, including the cornea, the cornea (including the epithelium, Descemet's membrane, and endothelium), the conjunctiva, the conjunctival sac, and the limbus, i.e. Point to the face.

[0094] As used herein, "pain" includes, but is not limited to, stabbing, dull, sharp or painful. Pain refers to the sensation of actual pain, either constant or intermittent, described as a tingling sensation. However, burning, stinging, roughness, foreign body sensation, dryness, sandiness, fatigue, itching, prickling It also refers to similar related descriptors such as sensitivity to light and dry eyes.

[0095] As used herein, ocular administration refers to administration to the cornea, conjunctiva, conjunctival sac, and corneoscleral junction, i.e., the cornea. This includes administration to all parts of the eye, including all parts of the ocular surface, such as the limbus.

[0096] As used herein, "ocular surface pain" refers to pain at the surface of the eye, for example, the cornea. Ocular pain is generally caused by external physical factors such as corneal surgery, inflammation, or other injury to the corneal surface. Ocular pain may be nociceptive pain caused by ocular or chemical injury stimuli. It also blocks pain messages being sent to the central nervous system and brain despite the presence of noxious stimuli. This is due to neuropathic pain, which can result from direct damage to the body's neurons. As used herein, "ocular surface pain" refers to nociceptive pain. and neuropathic pain.

[0097] As used herein, the term "visual analog scale" (VAS) refers to a scale that a subject typically uses to measure , a pain intensity scale that marks the location against a scale that aligns with the level of pain Pain was assessed on a 5-point scale, with a score of 0 being “no pain” and a score of “worst pain imaginable” or “worst pain imaginable.” For example, Hawker, et al. al.,Arthritis Care & Research 63(11),pp. See S240-S252 (November 2011). There are several other well-designed pain scales that can be used to help. A numeric rating scale (NRS) is used in which subjects use numbers to rate their pain. The numerical scale can be 1 to 10 or 1 to 100. The FACES pain scale combines pictures and numbers to grade pain. It can be used in children over 3 years of age and in adults. The six faces range from fair to very poor. A range of tones represent different facial expressions, each between 0 (smiling) and 10 (crying). The verbal pain intensity scale rates pain intensity on a scale of 1 to 100. Use verbal descriptions on a rating scale: no pain / mild pain / moderate pain Moderate pain / severe pain Very severe pain / no pain at all.

[0098] The Ocular Sensation Scale is a specific pain scale developed to measure the severity of eye pain. Caudle LE et al., Optom Vis Sci. 20 See 07 Aug;84(8):752-62. This scale measures pain, discomfort, Sensitivity or photosensitivity is usually categorized into five categories: "extreme," "severe," "moderate," "mild," or "none." This is measured by the category label.

[0099] The Ocular Pain Assessment Survey (OPAS) assesses changes in corneal and ocular surface pain and quality of life (QoL). The OPAS is a quantitative, multidimensional questionnaire specifically designed to assess pain Pain intensity, frequency of ocular and non-ocular pain, changes in QoL, contributing factors, associated factors and symptom relief Quantitative assessment of IL-16 expression allows for monitoring of therapeutic response. Ophthalmology July 123(7):1458-1468(2016 ) for more information.

[0100] As used herein, the term "visual task questionnaire" refers to the assessment of fixations that may worsen ocular pain. How much difficulty do you have performing certain tasks that require constant or prolonged staring? This refers to a questionnaire that asks subjects to subjectively rate how well their visual perception is improved. Also ask about the difficulties experienced while performing the task and associated coping mechanisms.

[0101] As used herein, ocular hyperemia refers to redness of the ocular surface. Ocular hyperemia can be caused by inflammation and / or It can be a clinical marker for eye irritation. Eye redness is typically assessed based on standard photographs. It is measured using the McMonnies scale with values ​​from 0 to 5.

[0102] As used herein, "placebo" refers to a total amount of a drug composition that does not contain any administered drug. This refers to an eye drop preparation containing all of the above ingredients.

[0103] As used herein, the term "about" refers to a range of the specified value plus 10%.

[0104] As used herein, a "polymorph" refers to a compound that has the same chemical composition but forms crystals. Refers to crystalline forms having different spatial arrangements of molecules, atoms and / or ions.

[0105] As used herein, a "solvate" refers to one or more compounds incorporated into a crystal lattice structure. A crystalline form of a molecule, atom, and / or ion that further contains a number of molecules of a solvent. The solvent molecules in the solvate may be present in an ordered and / or disordered arrangement. The solvent may contain either stoichiometric or non-stoichiometric amounts of solvent molecules. A solvate having a molecular weight of 1,2-dichlorophenyl ether may result from partial loss of solvent from a solvate. The product may be present as a dimer or oligomer containing two or more molecules of compound I within a crystal lattice structure. There may be.

[0106] As used herein, "amorphous" refers to a material that is not crystalline, that is composed of molecules, atoms, and / or ions. Amorphous solids do not exhibit definitive X-ray diffraction patterns.

[0107] As used herein, "substantially pure" when used in reference to a form refers to a compound. The purity of compound I is greater than 90% by weight, based on its weight, for example, 90, 91, 92, 9 3, 94, 95, 96, 97, 98 and 99% by weight, and further, for example, about 10 The remaining material may be other forms and and / or reaction impurities and / or process impurities arising from their preparation. The crystalline forms of Compound I are known at this time and can be obtained by means generally accepted in the art. It may be considered substantially pure by having a purity of greater than 90% by weight, as measured by Less than 10% by weight of the remaining material may be other forms of Compound I and / or reaction impurities and / or Contains processing impurities.

[0108] As used herein, "compound of formula I" or "Compound I" "Formula I" and "compound I" are used interchangeably and are shown below. The structure name is 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazo It means a compound having a benzonitrile group, and is known to those skilled in the art and has both No. 2005 / 113636, to Chen et al., which is hereby incorporated by reference in its entirety. No. 20510 and U.S. Pat. No. 8,349,852 ("Quinaz olinone derivatives useful as vanilloid The compounds can be synthesized using the procedures described in "Antagonists" below. [ka]

[0109] As used herein, the term "crystal form" in upper or lower case means "crystalline form," "modified form," or "multiple forms" The terms "crystalline form" or "polymorphic form" are used interchangeably and refer to a crystalline or polymorphic form of Compound I. Compound I may be used in amorphous or crystalline form. Additionally or alternatively, Various crystalline and polymorphic forms of Compound (I) may be used. A "polymorphic form" or "polymorph" of Compound (I) refers to a crystalline hydrate or other crystalline form of Compound (I). The term "solvates" is intended to include both organic and chemical solvates.

[0110] Any chemical formula given herein represents unlabeled and isotopically labeled forms of the compound. It is also contemplated that isotopically labeled compounds are compounds in which one or more atoms have a selected atomic mass or molecular weight. According to the formula given herein except that the atoms are replaced by the atoms having the quantification numbers Isotopes that may be incorporated into the compounds of the present disclosure include, for example, 3 H , 11 C. 13 C. 14 C and 15 These include isotopes of hydrogen, carbon, nitrogen, and oxygen, such as N. Thus, the method of the present invention can include, for example: 3 H and 14 Radioisotopes such as C or 2 H and 13 Any one of the above isotopes, including those that exist as non-radioactive isotopes such as C It should be understood that the composition may or may not include compounds incorporating the above. Such isotope-labeled compounds are useful for metabolic studies ( 14 C), reaction rate tests (e.g. 2 Hmata teeth 3 H), positron emission tomography (PET) including drug or substrate tissue distribution assays ( Detection or measurement of the tumor using PET (positron emission tomography) or single photon emission computed tomography (SPECT) are useful in imaging techniques or in radiotherapy of patients. Isotopically labeled compounds are usually For example, suitable isotopically labeled reagents may be substituted for previously utilized non-labeled reagents to provide a novel method for the preparation of fluorophores. They may be prepared by conventional techniques known to those skilled in the art.

[0111] The present invention includes all pharma- ceutically acceptable forms of the compounds useful according to the invention provided herein. As used herein, the term "pharmacologically acceptable salt" includes embodiments that include salts thereof. refers to derivatives of the disclosed compounds, the parent compound being one that has an acid or base moiety present in it. The compound is modified by converting it into a salt form. Examples of pharma- ceutically acceptable salts include amine salts. mineral or organic acid salts of basic residues such as carboxylic acids; alkali or organic salts of acidic residues such as carboxylic acids; Pharmaceutically acceptable salts include, but are not limited to, organic salts. These include the conventional non-toxic salts of the parent compound, for example, derived from non-toxic inorganic or organic acids. Pharmaceutically acceptable salts are prepared by conventional chemical methods, which contain a basic or acidic moiety. Typically, such salts can be synthesized from the free acid or base forms of these compounds. Form and water or organic solvent or a mixture of the two (usually ether, ethyl acetate, ethanol) (preferably in a non-aqueous medium such as alcohol, isopropanol or acetonitrile) The salts can be prepared by reacting the compound with a stoichiometric amount of an appropriate base or acid. No. 6,399,413, each of which is incorporated herein by reference in its entirety. Pharmaceutical Sciences,17th ed.,Mack Pub lishing Company, Easton, Pa., 1985, p. 1418 and Journal of Pharmaceutical Science,66,2(1 For example, preferred pharma- ceutically acceptable salts include amine salts. Examples of basic residues include, but are not limited to, mineral or organic acid salts of basic residues such as: The salt may be a hydrochloride salt. Other examples of suitable salts are described in US Pat. No. 6,399,413, the contents of which are hereby incorporated by reference in their entirety. No. 8,349,852, which is incorporated herein by reference.

[0112] As used herein, the phrase "pharmacologically acceptable" means any compound that is acceptable to the patient based on sound medical judgment. Within the limits of reasonable benefit / risk ratio, excessive toxicity, irritation, and allergy - Use in contact with human and animal tissues without reactions or other problems or complications "compounds, substances, compositions and / or dosage forms that are suitable for

[0113] Unless otherwise indicated, all component concentrations are in % weight / volume (% w / v). As is commonly understood, %w / v values ​​are used to determine the relative amount of a particular component or ingredient in a formulation. It is generally understood that equivalent concentrations can be expressed in different units. For example, , a concentration of 0.1% w / v can also be expressed as a 1 mg / ml solution.

[0114] Unless otherwise specified, weights or dosages referred to herein for compounds of formula I are or salts or prodrugs thereof, which may be different to achieve the desired therapeutic effect. For example, the weight or dosage of the compound itself is not the weight or dosage of the compound itself. The weight or dosage of the corresponding salt of a compound suitable for combination depends on the molecular weight of the salt and the compound itself. It may be calculated based on a ratio.

[0115] Crystalline Form B of Compound I is disclosed in U.S. Pat. No. 8,349, incorporated herein by reference. Polymorph B is described in US Pat. No. 852. Polymorph B has 9.3, 10.6 and 14.4±0.2 2θ 3 , characterized by an X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from In some embodiments, polymorph B is represented by the formulas 9.3, 10.6, 14.4, 15. At least three 2θ values ​​selected from 0.5, 17.9, 19.9, and 23.4±0.2°2θ It is characterized by an X-ray diffraction pattern having peaks.

[0116] Crystalline Form of Compound I In one aspect, the present invention provides a method for determining the angle of refraction selected from 7.2, 12.7 and 21.4±0.2 degrees 2θ. Compound I is characterized by an X-ray diffraction pattern having three or more peaks at 2θ values. In some embodiments, crystalline form A has a molecular weight of 7.2, 12.7, 1 2θ selected from 3.9, 18.1, 21.4, 25.1 and 26.8±0.2°2θ It is characterized by an X-ray diffraction pattern with three or more peaks at 100 nm. In embodiments, crystalline form A is 7.2, 12.7, 13.3, 13.9, 14.5, 15. 6, 18.1, 19.9, 21.4, 22.8, 25.1, 26.8, 27.8, 29. 3 or more, 4 or more, 5 or more, 6 or more at 2θ values ​​selected from 0±0.2°2θ It is characterized by an X-ray diffraction pattern with seven or more peaks.

[0117] Crystalline Form A can be prepared by cooling a hot solution of the free base of Compound I in methanol to approximately 0° C. and crystallizing compound I as crystalline form A.

[0118] In one embodiment, crystalline Form A of Compound I is provided in substantially pure form. This crystalline Form A of Compound I in substantially pure form can be used in pharmaceutical compositions, e.g., as described herein. In some embodiments, the present disclosure provides a compound in crystalline form A. In some embodiments, the present disclosure provides pharmaceutical formulations comprising Compound I. providing a suspension, wherein at least about 10%, at least about 20%, at least about 10% of Compound I; About 30%, at least about 40%, at least about 50%, at least about 60%, at least About 70%, at least about 80% or at least 90% is present as crystalline form A.

[0119] In one aspect, the present invention provides a method for determining whether a 2θ angle is 7.4, 14.9, or 19.1±0.2° 2θ. Compound I is characterized by an X-ray diffraction pattern having three or more peaks at θ values. In some embodiments, crystalline form C is selected from the group consisting of 7.4, 14.1, 14 At 2θ values ​​selected from 0.9, 16.4, 19.1, 26.1, 31.2±0.2°2θ It is characterized by an X-ray diffraction pattern having three or more peaks. In the present study, crystal form C had the following average molecular weights: 7.4, 14.1, 14.9, 16.4, 19.1, 24.8, 26.1, 28.4, 31.2±0.2°2θ at 3 or more, 4 or more and characterized by an X-ray diffraction pattern having 5 or more, 6 or more, or 7 or more peaks. can be done.

[0120] Crystalline form C can be prepared by heating crystalline form A.

[0121] In one embodiment, crystalline Form C of Compound I is provided in substantially pure form. This crystalline Form C of Compound I in a substantially pure form can be used in pharmaceutical compositions, e.g., as described herein. In some embodiments, the present disclosure provides a method for the preparation of compound C in crystalline form C. In some embodiments, the present disclosure provides pharmaceutical formulations comprising Compound I. providing a suspension, wherein at least about 10%, at least about 20%, at least about 10% of Compound I; About 30%, at least about 40%, at least about 50%, at least about 60%, at least About 70%, at least about 80% or at least 90% is present as crystalline form C.

[0122] In one aspect, the present invention provides an optical fiber having a wavelength of 12.7, 16.7, 22.6±0.2 degrees 2θ. Compound I is characterized by an X-ray diffraction pattern having three or more peaks at 2θ values. In some embodiments, crystalline form E is represented by the formula: 12.7, 15.1, 2θ selected from 16.7, 22.6, 27.1, 27.7, 28.5±0.2°2θ It is characterized by an X-ray diffraction pattern with three or more peaks at 100 nm. In some embodiments, polymorph E of compound I has an onset melting temperature of about 281° C. In embodiments, crystalline form E is 9.1, 11.9, 12.7, 13.8, 15.1, 16. 7, 18.3, 21.3, 22.6, 24.4, 27.1, 27.7, 28.5, 37. 8±0.2°2θ, 3 or more, 4 or more, 5 or more, 6 or more, or It is characterized by an X-ray diffraction pattern with seven or more peaks.

[0123] Crystalline Form E can be obtained by heating the hydrate form of Compound I to a temperature above about 250° C. or about 260° C. and heating to obtain compound I as crystalline form E. In some cases, the heating is carried out in a drying oven.

[0124] In one embodiment, crystalline form E of compound I is provided in substantially pure form. This crystalline form E of compound I in a substantially pure form can be used in pharmaceutical compositions, e.g., as described herein. In some embodiments, the present disclosure provides a compound in crystalline form E. In some embodiments, the present disclosure provides pharmaceutical formulations comprising Compound I. providing a suspension, wherein at least about 10%, at least about 20%, at least about 10% of Compound I; About 30%, at least about 40%, at least about 50%, at least about 60%, at least About 70%, at least about 80% or at least 90% is present as crystalline form E.

[0125] In one embodiment, the present invention relates to a crystalline hydrate of Compound I (polymorph F). In terms of form, the crystalline hydrate of compound I is selected from 6.6, 14.4, and 18.3±0.2°2θ. It is characterized by an X-ray diffraction pattern having three or more peaks at selected 2θ values. In some embodiments, the crystalline hydrate is 6.6, 11.9, 14.4, 18.3, 23 The sample had three or more peaks at 2θ values ​​selected from 0.9, 26.5, and 29.2±0.2°2θ. It is characterized by an X-ray diffraction pattern that corresponds to the

[0126] In some embodiments, the crystalline hydrate is 6.7, 11.9, 12.8, 14.4, 1 5.6, 16.3, 18.3, 19.5, 22.7, 23.9, 24.7, 25.6, 2 3 or more, 4 or more, 5 or more at 2θ values ​​selected from 6.5, 29.2±0.2°2θ , characterized by an X-ray diffraction pattern having six or more or seven or more peaks.

[0127] Crystalline Form F can be obtained by equilibration of a slurry of Compound I in a mixture of water and a water-miscible solvent. It may be prepared by crystallizing compound I as crystalline form F. In certain embodiments, The water-miscible solvent is acetone. In some embodiments, the equilibration is for about 12 hours. In some embodiments, the equilibration is performed for about 18 hours, or for about 24 hours, or for about 48 hours. The polymerization is carried out at room temperature, ie, about 25°C.

[0128] In one embodiment, crystalline form F of compound I is provided in substantially pure form. This crystalline form F of compound I in a substantially pure form can be used in pharmaceutical compositions, e.g., as described herein. In some embodiments, the present disclosure provides compound I as a crystalline hydrate. In some embodiments, the present disclosure provides a pharmaceutical formulation comprising the polymorphic form Form F. and providing an ophthalmic suspension of Compound I, wherein at least 10% of Compound I, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, or at least 90% are crystalline hydrates. (Polymorph F).

[0129] In one aspect, the present invention relates to a crystalline methanol solvate form (polymorph G) of Compound I. In some embodiments, the crystalline methanol solvate of compound I has a molecular weight of 6.1, 14.5 , 22.7±0.2°2θ, or 3 or more peaks at 2θ values ​​selected from In some embodiments, the crystalline methanol solvate is characterized by a turn. , 6.1, 12.2, 14.5, 18.0, 22.7, 24.6±0.2°2θ It is characterized by an X-ray diffraction pattern having three or more peaks at the 2θ values ​​specified.

[0130] Polymorphic form G was prepared by equilibrating a slurry of compound I in methanol to convert compound I to crystalline form G. In some embodiments, the equilibration is for about 12 hours. In some embodiments, the incubation is performed for about 18 hours, or for about 24 hours, or for about 48 hours. Equilibration is carried out at room temperature, ie, about 25°C.

[0131] In one embodiment, crystalline form G of compound I is provided in substantially pure form. This crystalline form G of compound I in a substantially pure form can be used in pharmaceutical compositions, e.g., as described herein. In some embodiments, the present disclosure provides compound I as a crystalline metabolite. In some embodiments, the present disclosure provides a pharmaceutical formulation comprising the compound as a polymorphic form (polymorph G). provides an ophthalmic suspension of Compound I, wherein at least 10% of Compound I, at least About 20%, at least about 30%, at least about 40%, at least about 50%, at least About 60%, at least about 70%, at least about 80%, or at least 90% crystalline metal It exists as a ethanol solvate (polymorph G).

[0132] In one aspect, the present invention relates to a crystalline acetonitrile solvate (crystalline form J). In some embodiments, the crystalline acetonitrile solvate of Compound I has a viscosity of 8.2, 17.0, X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 23.8±0.2°2θ In some embodiments, the crystalline acetonitrile solvate is Choose from 8.2, 11.8, 17.0, 22.8, 23.8, and 27.6±0.2°2θ. It is characterized by an X-ray diffraction pattern having three or more peaks at selected 2θ values. In some embodiments, the crystalline acetonitrile solvate has an average molecular weight of 8.2, 11.8, 17. 3 at 2θ values ​​selected from 0, 22.8, 23.8, 27.6, and 31.4±0.2°2θ X-ray diffraction pattern having one or more, four or more, five or more, six or more, or seven or more peaks It is characterized by:

[0133] To prepare the crystalline acetonitrile solvate, equilibrate a slurry of Compound I with acetonitrile. In some embodiments, the compound in the slurry may be prepared by crystalline form A. In some embodiments, the equilibration is for about 12 hours, about 18 hours, or about 24 hours. In some embodiments, the equilibration is carried out at room temperature, i.e., about 25° C. It will be carried out.

[0134] In one embodiment, the crystalline acetonitrile solvate of Compound I is in substantially pure form. This crystalline acetonitrile solvate of Compound I in substantially pure form is provided: They may be used in pharmaceutical compositions, such as ophthalmic formulations, as described herein. In one embodiment, the present disclosure provides a pharmaceutical composition comprising Compound I as a crystalline acetonitrile solvate (polymorph J). In some embodiments, the present disclosure provides an ophthalmic suspension of Compound I. wherein at least 10%, at least about 20%, at least about 30%, or at least about 10% of Compound I At least about 40%, at least about 50%, at least about 60%, at least about 70%, At least about 80% or at least 90% is a crystalline acetonitrile solvate (polymorph J). It exists as.

[0135] In one aspect, the present invention provides a method for determining whether a 2θ angle is 5.3, 12.3, or 22.4±0.2° 2θ. Compound I is characterized by an X-ray diffraction pattern having three or more peaks at θ values. In some embodiments, the crystalline form K has an average molecular weight of 5.3, 6.5, 10. 3 at 2θ values ​​selected from 5, 12.3, 17.2, 19.3, and 22.4±0.2°2θ and X-ray diffraction patterns having one or more, four or more, five or more, or six or more peaks. To be constrained.

[0136] Crystal form K was obtained by evaporative crystallization of compound I in acetone. It can be prepared by crystallization from 100% aqueous solution of 1,2-dichlorophenyl ether.

[0137] In one embodiment, crystalline form K of compound I is provided in substantially pure form. This crystalline form K of compound I in a substantially pure form can be used in pharmaceutical compositions, e.g., as described herein. In some embodiments, the present disclosure provides compound I in polymorph K. In some embodiments, the present disclosure provides a pharmaceutical formulation comprising Compound I as an ophthalmic solution. providing a suspension, wherein at least about 10%, at least about 20%, at least about 10% of Compound I; About 30%, at least about 40%, at least about 50%, at least about 60%, at least About 70%, at least about 80% or at least 90% is present as the Form K polymorph.

[0138] In one aspect, the present invention provides a method for determining the angle of incidence of a 2θ angle selected from 7.1, 8.7, 10.6±0.2 degrees 2θ. The results of compound I are characterized by an X-ray diffraction pattern having three or more peaks at In some embodiments, crystalline form L has a molecular weight of 3.5, 7.1, 8.7, Three or more 2θ values ​​selected from 10.6, 12.2, 19.1, and 22.4±0.2°2θ In some embodiments, the compound is characterized by an X-ray diffraction pattern having peaks above 100 nm. , and crystal form L is 3.5, 7.1, 8.7, 10.6, 11.1, 12.2, 19.1, 21.1, 22.4, 23.4±0.2°2θ, 3 or more, 4 or more and characterized by an X-ray diffraction pattern having 5 or more, 6 or more, or 7 or more peaks. can be done.

[0139] Crystal form L was obtained by precipitation of a solution of compound I in acetone by adding a hydrocarbon solvent. It can be prepared by crystallizing compound I in crystalline form L. In certain embodiments, the hydrocarbon solvent is pentane, hexane, or heptane. The hydrocarbon solvent is hexane.

[0140] In one embodiment, crystalline form L of compound I is provided in substantially pure form. This crystalline form L of compound I in a substantially pure form can be used in pharmaceutical compositions, e.g., as described herein. In some embodiments, the present disclosure provides compound I in polymorph L. In some embodiments, the present disclosure provides a pharmaceutical formulation comprising Compound I as an ophthalmic solution. providing a suspension, wherein at least about 10%, at least about 20%, at least about 10% of Compound I; About 30%, at least about 40%, at least about 50%, at least about 60%, at least About 70%, at least about 80% or at least 90% is present as the L polymorph.

[0141] In some embodiments, the present invention provides formulations of compounds of formula I. In some embodiments, the formulation is an aqueous suspension of the compound of formula I. In some embodiments, the suspension is about 0.5% w / v to about 1.5% w / v, about 0.5% w / v to about 2.5% w / v, about 0 .5%w / v ~ approx. 3.5%w / v, approx. 0.5%w / v ~ approx. 3.0%w / v, approx. 1.0%w / v ~ approx. 2.5%w / v, approx. 1.5%w / v ~ approx. 3.0%w / v, approx. 0.5%w / v ~ approx. In some embodiments, the topical ophthalmic formulation comprises a compound of formula I at a concentration of 2.5% w / v. The concentration of the compound of formula I in the formulation for use is at least about 0.5% w / v, at least About 1.0% w / v, at least about 1.5% w / v, at least about 2.0% w / v or less In some embodiments, in formulations for topical use, The concentration of the compound of formula I is about 5.0% w / v or less, about 4.5% w / v or less, about 4.0% w / v or less. In certain embodiments, the amount of glycerol in the blood is about 3.5% w / v or less, about 3.0% w / v or less, about 3.5% w / v or less, or about 3.0% w / v or less. The concentration of the compound of formula I in a formulation for topical use is about 0.5% w / v, about 1.0% w / v, approx. 1.5%w / v, approx. 2.0%w / v, approx. 2.5%w / v, approx. 3.0%w / v is about 3.5% w / v. When expressed in mg / ml, in some embodiments The compound of formula I is preferably from about 5 mg / ml to about 35 mg / ml, more preferably from about 5 mg / ml to about 25 mg / ml. / ml or about 5 mg / ml to about 15 mg / ml, about 5 mg / ml to about 30 mg / ml, about 10 mg / ml to about 25 mg / ml, about 15 mg / ml to about 30 mg / ml, or about 5 mg In some embodiments, the topical administration of the agent to a subject is at a concentration of about 25 mg / ml to about 30 mg / ml. The concentration of the compound of formula I in the formulation for such use is at least about 5 mg / ml, at least About 10 mg / ml, at least about 15 mg / ml, at least about 20 mg / ml or less In some embodiments, the formulation for topical use is at least about 25 mg / ml. The concentration of the compound of formula I is about 50 mg / ml or less, about 45 mg / ml or less, about 40 mg / ml or less. ml or less, about 35 mg / ml or less, or about 30 mg / ml or less. , the compound of formula I is at about 5 mg / ml, about 10 mg / ml, about 15 mg / ml, about 20 mg / ml, about 25mg / ml, about 30mg / ml or about 35mg / ml In some embodiments, the compound of formula I is present in polymorph A, polymorph B, polymorph C, polymorph E, , polymorph F (hydrate H A ), polymorph J (acetonitrile solvate S A ), polymorph G (Meta Nol solvate S B ), polymorph K, polymorph L or a combination thereof. In embodiments, Compound I is present in the ophthalmic formulations described herein in substantially pure form in polymorph B. In some embodiments, Compound I is present in the ophthalmic formulations described herein. It exists as polymorph A in qualitatively pure form. In some embodiments, compound I is It is present in substantially pure form as polymorph C in the ophthalmic formulations described herein. In embodiments, Compound I is present in the ophthalmic formulations described herein in a substantially pure form as a polymorph. In some embodiments, compound I is present as E in the ophthalmic formulations described herein. In some embodiments, compound I is present in substantially pure form as polymorph F. is present in the ophthalmic formulations described herein in substantially pure form as polymorph K. In some embodiments, Compound I is present in the ophthalmic formulations described herein in substantially pure form. In certain embodiments, compound I exists as form L. In certain embodiments, compound I exists as form L in two or more different polymorphic forms. In some embodiments, compound I is present in the formulation as a mixture of polymorph B and E, polymorphs B and F, polymorphs B and C, polymorphs A and C, polymorphs A and F in a ratio of about 1:9 It exists as a mixture in a ratio of about 9 to about 99:1.

[0142] In some embodiments, the formulation further comprises at least one ophthalmically acceptable excipient. Included.

[0143] In some embodiments, the formulation includes an ophthalmically acceptable surfactant. In embodiments, the surfactant is an anionic surfactant. The ionic surfactant is C 10 ~C 22 Alkyl sulfate, C 10 ~C 22 Alkyl (oligo Oxyalkylene) Sulfates, C4-C 22 Alkyl sulfosuccinate esters, C 10 ~C 22 Acyl sarcosinate and C 10 ~C 22 alkyl carboxylates; The oligooxyalkylene moiety is 1 to 5 oxy-C1-C6 alkylene moieties, e.g. , oxyethylene moieties. Anionic surfactants are those which are alkali metal, e.g. Ammonium, C1-C3 alkyl ammonium, tri(C1-C3 alkanol) ammonium ammonium, for example, triethanolammonium, di(C1-C3 alkanol)ammonium and ammonium cation. The concentration of the surfactant is about 0.005 to 0.1 g / L or 0.005 to 0.05 g / L. In some embodiments, the surfactant is a cationic surfactant. Non-limiting examples of surfactants include alkylamine salts, alkylamine polyoxyethylene fatty acid triethanolamine monoester salt, acylaminoethyl diethylamine amine salt, fatty acid polyamine condensate, alkyl imidazoline, 1-acylaminoethyl-2 -alkylimidazoline, 1-hydroxyethyl-2-alkylimidazoline, etc. , its salts such as chlorhexidine, chlorhexidine or its salts, e.g. In some embodiments, the cationic surfactant is about 0.001% w / v to about 5% w / v, or about 0.001% w / v to about 1% w / v, or about 0.001% w / v to about 0.1% w / v, or about 0.001% w / v to about 0.01% w / v, or from about 0.001% w / v to about 0.005% w / v.

[0144] In certain embodiments, the surfactant is a non-ionic surfactant. In the present embodiment, the non-ionic surfactants include polysorbate surfactants, ethylene oxide and polysorbate. Propylene oxide block copolymer surfactants (e.g., Pluronic or Tetronic types) The surfactants are poloxamers, tyloxapol, or combinations thereof. The alcohols are non-ionic liquid polymers of the alkylaryl polyether alcohol type. Poloxamers consist of two hydrophilic chains of polyoxyethylene (poly(ethylene oxide)). It consists of a central hydrophobic chain of adjacent polyoxypropylene (poly(propylene oxide)). In certain embodiments, the nonionic triblock copolymer is a nonionic interfacial triblock copolymer. The active agent is tyloxapol. In some embodiments, the tyloxapol is at least At least about 0.001% w / v, at least about 0.01% w / v, at least about 0.02% w / v at least about 0.03% w / v, at least about 0.04% w / v, and % w / v or less, about 0.5% w / v or less, about 0.3% w / v or less, or about 0.2% w / v or less , in an amount of about 0.1% w / v or less, or about 0.08% w / v or less. In the form, the nonionic surfactant is about 0.03% w / v to 0.08% w / v or about 0. The primary active ingredient is tyloxapol, present in an amount of 0.05% w / v.

[0145] In some embodiments, the formulation comprises about 15% w / v to 20% w / v poloxamer interface. In some embodiments, the formulation comprises about 15%, about 15.5%, about 16%, About 16.5%, about 17%, about 17.5%, about 18%, about 18.5%, about 19%, about 19. 5% or about 20% w / v poloxamer. In certain embodiments, the formulation contains about 17. In a further specific embodiment, the poloxamer is 5% w / v. In certain embodiments, the surfactant is substantially all tyloxamer 407. It is a rule.

[0146] In some embodiments, the formulation comprises a suspending agent. In some embodiments, the suspending agent , carbomer, hydroxypropyl methylcellulose (hypromellose), polyethylene glycols or combinations thereof. Carbomers have a network of cross-linked polymer chains. The polymer is characterized as having carboxylic acid functionality. They are often copolymers of carbomers and may contain 2 to 7 carbon atoms per functional group. That is, for example, crosslinked with allyl sucrose or allyl ether of pentaerythritol. The most widely used synthetic high molecular weight polymers of acrylic acid are water-soluble and water-swellable carbomers. Lubomer is available from a variety of suppliers under the trade name CARBOPOL®. In certain embodiments, the carbomer is carbomer homopolymer type B. In an embodiment, the carbomer is CARBOPOL® 934P (Carbomer 93 4P), 940 or 974P. In some embodiments, the suspending agent is carbomer. and at least about 0.05% w / v, at least about 0.1% w / v or at least about 0.2% w / v and not more than about 1.0% w / v, not more than about 0.6% w / v, or not more than about 0.5% w / v In certain embodiments, the suspending agent is present in the formulation in an amount of 0.1 to 1.0% w / v. and in an amount of 0.1% w / v to about 0.3% w / v or about 0.2% w / v of the formulation exists within.

[0147] In some embodiments, the suspending agent is hydroxypropyl methylcellulose. In certain embodiments, the hydroxypropyl methylcellulose is at least about 0.05% w at least about 0.1% w / v or at least about 0.25% w / v, and Less than 0.8% w / v, less than about 1.0% w / v, less than about 0.8% w / v or less than about 0.6% w / v In some embodiments, hydroxypropyl methyl Cellulose is about 0.1% w / v to about 0.8% w / v; about 0.1% w / v to about 0.6% w / v; approx. 0.25%w / v ~ approx. 0.8%w / v; approx. 0.4%w / v ~ approx. 0.6%w / v is present in the formulation in an amount of

[0148] In some embodiments, the suspending agent is a polyethylene having a molecular weight of at least about 200 Da. In some embodiments, the PEG is at least about 400, 1,000, 2,000, 3,000, 4,000, 6,000 or about 10,0 In some embodiments, the suspending agent has a molecular weight of about 200 Da to about 200 Da. The molecular weight of the polymer is 1,000 Da. In embodiments, the PEG is about 400, 1,000, 2,000, 3,000, 4,000, In some embodiments, the PEG has a molecular weight of about 6,000 or about 10,000 Da. is at least about 1% w / v, at least about 2% w / v, at least about 3% w / v and in an amount of less than about 10% w / v, less than about 9% w / v, or less than about 8% w / v in the formulation. In certain embodiments, the suspension is present in an amount of about 4% w / v to about 9% w / v, about 5% w / v, In certain embodiments, the PEG 400 is at a concentration of about 8% w / v or about 7% w / v. The suspension may be about 1% w / v to about 4% w / v, about 1% w / v to about 3% w / v, or about 2% w / v. The concentration of PEG 6000 is

[0149] In certain embodiments, the suspending agent is a combination of two or more suspending agents. The suspending agent is substantially all carbomer.

[0150] In some embodiments, the suspending agent may provide the formulation with a desired viscosity. The appropriate viscosity allows Compound I to remain in suspension in the formulation without settling or solidifying. In some embodiments, the viscosity of the formulation is about 10 cP to about 200 cP (centipoise), about 20 cP to about 200 cP, or about 20 cP to about 1 In some embodiments, the formulation viscosity is at least about 10 cP, 20 cP, or less. Viscosity measurements for the formulations are at least about 150 cP, 50 cP, 100 cP, or at least about 150 cP. Brookf uses a CP-42 spindle at either 3 rpm or 60 rpm. Viscosity is measured using a .ield viscometer. Viscosity is usually measured at room temperature, i.e., 25°C. .

[0151] In some embodiments, the formulation comprises an osmotic agent. As used herein, the terms "polyol" and "polyol" refer to each other. At least one hydroxyl group is present at each of two adjacent carbon atoms that are not in a trans configuration. The polyol may be any compound having a carboxylic acid group. The polyol may be any compound having a carboxylic acid group such that the resulting complex is water soluble and As long as it is pharma- ceutically acceptable, it may be linear or cyclic, substituted or unsubstituted, or a mixture thereof. Examples of such compounds include: sugars, sugar alcohols, sugar acids and uronic acids. In some embodiments, the osmotic agent is mannitol, glycerin, xylitol. , sorbitol and propylene glycol or combinations thereof. , polyols such as sugars, sugar alcohols and sugar acids. In certain embodiments, the composition comprises: In some embodiments, the polysaccharide in the formulation comprises mannitol, glycerin, or a combination thereof. The amount of riol is about 0.05% w / v to about 10% w / v, about 0.1% w / v to about 8% w / v , about 0.1% w / v to about 7% w / v, and about 0.1% w / v to about 5% w / v. In an embodiment, the osmotic agent is mannitol or glycerin, which is present at 0.1% w / v ~ about 5% w / v or about 0.2% w / v, about 0.3% w / v, about 0.4% w / v, about 0.5 %w / v, approx. 1%w / v, approx. 2%w / v, approx. 2.5%w / v, approx. 3.0%w / v, approx. 3. in the formulation in an amount of about 5% w / v, about 4.0% w / v, about 4.5% w / v or about 5% w / v In certain embodiments, the osmotic agent is mannitol. The osmotic agent is glycerin.

[0152] In some embodiments, the formulation comprises a buffer. Examples of buffer substances include acetate, Ascorbate, borate, bicarbonate, carbonate, citrate, edetate (EDTA ) Gluconate, lactate, phosphate, propionate and TRIS (tromethamine) buffers In certain embodiments, the buffer is a phosphate buffer system. In this example, the buffer is a tromethamine buffer. The amount of buffer substance added is usually physiological. The amount of water added is the amount necessary to ensure and maintain a pH range acceptable for some embodiments. The pH range is about 4 to about 9, about 4.5 to about 8.5, about 5.0 to about 8.0, about 5.5 to about In some embodiments, the pH is in the range of about 6.0, about 6.4 to about 8.4. 0. In certain embodiments, the pH is about 7.4.

[0153] In some embodiments, the formulation comprises a salt. In some embodiments, the salt is sodium chloride. In certain embodiments, the chlorine is sodium chloride, potassium chloride, calcium chloride, or magnesium chloride. In certain embodiments, the salt is sodium chloride. In certain embodiments, the salt is at least about 0.01% w at least about 0.02% w / v, at least about 0.03% w / v, at least about 0 0.04% w / v and not more than about 0.5% w / v, not more than about 0.4% w / v, not more than about 0.3% In particular, the amount of about 0.1% w / v or less, about 0.2% w / v or less, or about 0.1% w / v or less. In certain embodiments, the salt is present at about 0.01% w / v to about 0.5% w / v, about 0.02% w / v, ~0.4%w / v, approx.0.03%w / v~0.3%w / v, approx.0.04%w / v~approx. 0.2% w / v, about 0.05% w / v to about 0.1% w / v. In an embodiment, the salt is sodium chloride and is about 0.02% w / v to about 0.07% w / v 0.05% w / v or about 0.05% w / v.

[0154] In some embodiments, the formulations described herein contain from about 200 to about 450 kilograms. Milliosmoles per kg (mOsm / kg), about 200 to about 400 mOsm / kg, about 20 Osmolality of 0 to about 300 mOsm / kg or about 240 to about 360 mOsm / kg has.

[0155] In some embodiments, the formulations may be self-preserving and do not contain preservatives. In embodiments, the formulation includes a preservative. In some embodiments, the preservative includes polyhexane. Silmethylene biguanidine (PHMB), polymeric quaternary ammonium compounds (e.g., Polyquaternium-1), benzalkonium chloride (BAK), chlorite preservatives or other Chlorine-containing preservatives such as, but not limited to, those.

[0156] In some embodiments, the preservative is an ophthalmically acceptable polymeric quaternary ammonium Compounds of this type are disclosed in U.S. Pat. No. 3,931,319; U.S. Pat. No. 4,027,020; U.S. Pat. No. 4,407,791; U.S. Pat. ,525,346; U.S. Pat. No. 4,836,986; U.S. Pat. No. 5,0 Nos. 37,647; and 5,300,287; and International Publication No. 91 / 09523 (Dziabo et al.). In this state, the polymeric ammonium compounds have a number average molecular weight between 2,000 and 30,000. Also known as POLYQUAD® or ONAMERM® In a further specific embodiment, the number average molecular weight is 3.0 The range is between 00 and 14,000.

[0157] When used, polymeric quaternary ammonium compounds generally comprise 0.00001 to 0.00001% of the formulation. Use in amounts greater than 0.0003 w / v% or greater than 0.0007 w / v% In addition, polymeric quaternary ammonium compounds, when used in formulations, generally 0.03 w / v%, less than about 0.003 w / v%, or less than about 0.0015 w / v% of the formulation In some embodiments, the polymeric quaternary amines in the formulation are used at concentrations that are less than 50% by weight. The concentrations of ammonium compounds are as follows: greater than about 0.0003 w / v% but not greater than about 0 Less than .003 w / v%; greater than about 0.0003 w / v% but less than about 0.0015 w / v% 0.0007% w / v but less than about 0.003% w / v; and In certain embodiments, the formulation comprises more than about 0.0015 w / v%. Contains polyquaternium 1 at a concentration of 0.1% w / v.

[0158] In some embodiments, the formulation comprises at least about 0.0005% w / v of the formulation, about 0. 0.001 w / v% or more than 0.007 w / v% and about 0.1 w / v% of the ophthalmic composition %, less than about 0.02 w / v%, or less than about 0.0035 w / v%. Any of the lower limits for the concentration of BAK is equal to any of the upper limits for the concentration of BAK. It is specifically contemplated that combinations of BA may be used in certain embodiments. The concentration of K is as follows: greater than about 0.001 w / v% but less than about 0.02 w / v%. Less than about 0.007 w / v%; More than about 0.001 w / v% but less than about 0.0035 w / v% % but less than about 0.02 w / v%; and greater than about 0.007 w / v% but less than about 0.00 Less than 35 w / v%.

[0159] In some embodiments, 4-(7-hydroxy-2-isopropyl) propyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or their salts, co-crystals or polymorphs, and Selected from the group consisting of surfactants, suspending agents, isotonicity agents, buffers, preservatives, salts and preservatives. One or more excipients Described herein is an aqueous formulation comprising:

[0160] In some embodiments, 4. present as a suspension in the formulation in an amount of about 0.5% w / v to about 3.5% w / v -(7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)- Benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof, and Selected from the group consisting of surfactants, suspending agents, isotonicity agents, buffers, preservatives, salts and preservatives. One or more excipients Described herein is an aqueous formulation comprising:

[0161] In some embodiments, 4-(7-hydroxy-2-isopropyl-4-oxopropyl) (4H-quinazolin-3-yl)-benzonitrile (Compound I) or its salt, cocrystal or or polymorphs, and Selected from the group consisting of surfactants, suspending agents, isotonicity agents, buffers, preservatives, salts and preservatives. One or more excipients Described herein is an aqueous formulation comprising:

[0162] In some embodiments, As a suspension, 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazo (Compound I) or its salt, cocrystal or polymorph, Beauty Selected from the group consisting of surfactants, suspending agents, isotonicity agents, buffers, preservatives, salts and preservatives. One or more excipients Described herein is an aqueous formulation comprising:

[0163] In some embodiments, the present disclosure provides: 4-, which is present as a suspension in the formulation in an amount of about 0.5% w / v to about 3.5% w / v. (7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-be benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof; Surfactants, Suspension agents, and one or more excipients selected from the group consisting of osmotic agents, buffers, preservatives, salts and preservatives; An aqueous formulation comprising:

[0164] In some embodiments, the invention described herein comprises: 4-, which is present as a suspension in the formulation in an amount of about 0.5% w / v to about 3.5% w / v. (7-Hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-be benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof; Non-ionic surfactants; Suspension agents; Osmotic agents; buffer; Salt; and The formulation optionally contains a preservative.

[0165] In some embodiments, the invention described herein comprises: 4-(7-hydroxy-2-isopropyl) (4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or a suspension of a salt, co-crystal or polymorph of Non-ionic surfactants; Suspension agents; Osmotic agents; buffer; salt; Optionally, a preservative; and The formulation contains up to 100% qs water.

[0166] In some embodiments, the invention described herein comprises: 4-(7-hydroxy-2-isopropyl) (4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or a suspension of a salt, co-crystal or polymorph of Tyloxapol, poloxamer or similar in an amount of about 0.01% w / v to 0.2% w / v a nonionic surfactant selected from the combination of Hydroxypropyl methylcellulose, polyethylene glycol or carbomer homopoly A suspending agent selected from the group consisting of mer-B type; an osmotic agent selected from polyols in an amount of about 0.05% w / v to about 10% w / v; a buffer selected from edetate, phosphate, borate or a combination thereof; Salt; and Contains up to 100% qs water; and The formulation has a pH range of about 5.5 to about 8.0.

[0167] In some embodiments, the invention described herein comprises: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. 4-(7-hydroxy-2-isopropyl-4-oxo-4H- Quinazoline-3-yl)-benzonitrile (Compound I) or its salts, co-crystals or polymorphs Suspension of the body, Tyloxapol in an amount of about 0.04% w / v to about 0.06% w / v, about 0.005% A non-isopropyl ether selected from poloxamers or combinations thereof in an amount of 0.12% w / v to 0.5% w / v. ionic surfactants; Hydroxypropyl methylcellulose in an amount of about 0.1% w / v to about 0.8% w / v , polyethylene glycol in an amount of about 2% w / v to about 8% w / v, about 0.05% w / v Carbomer homopolymer type B or combinations thereof in an amount of v to about 0.5% w / v Suspension agents to be used; mannitol or glycerin in an amount of about 0.1% w / v to about 5% w / v. osmotic agents; a buffer selected from edetate, phosphate, borate, tromethamine or combinations thereof; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; Water up to 100% qs, and The formulation has a pH range of about 5.5 to about 8.0.

[0168] In some embodiments, the invention described herein comprises: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. 4-(7-hydroxy-2-isopropyl-4-oxo-4H- Quinazoline-3-yl)-benzonitrile (Compound I) or its salts, co-crystals or polymorphs Suspension of the body, Tyloxapol in an amount of about 0.04% w / v to about 0.06% w / v; Carbomer homopolymer type B in an amount of about 0.05% w / v to about 0.4% w / v; glycerin in an amount of about 0.5% w / v to about 5% w / v; a buffer selected from edetate, phosphate, borate, tromethamine or combinations thereof; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; Water up to 100% qs, and The formulation has a pH range of about 5.5 to about 8.0.

[0169] In some embodiments, the invention described herein comprises: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. 4-(7-hydroxy-2-isopropyl-4-oxo-4H- A suspension of polymorphic form B of quinazolin-3-yl)-benzonitrile (Compound I); Tyloxapol in an amount of about 0.04% w / v to about 0.06% w / v; Carbomer homopolymer type B in an amount of about 0.05% w / v to about 0.4% w / v; glycerin in an amount of about 0.5% w / v to about 5% w / v; a buffer selected from edetate, phosphate, borate, tromethamine or combinations thereof; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; Water up to 100% qs, and The formulation has a pH range of about 5.5 to about 8.0.

[0170] In some embodiments, the invention described herein comprises: About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2. 4-(7-hydroxy-2-isopropyl-4-oxo-4H- A suspension of polymorphic form B of quinazolin-3-yl)-benzonitrile (Compound I); about 0.05% w / v tyloxapol; Carbomer homopolymer type B at approximately 0.2% w / v; glycerin at about 2.0% w / v; Tromethamine buffer; About 0.05% w / v sodium chloride; and Water up to 100% qs, and A formulation comprising a pH in the range of about 6.4 to about 8.4; The formulation does not contain preservatives.

[0171] In some embodiments, an acid or base, such as hydrochloric acid, sodium hydroxide, or a combination thereof, In certain embodiments, hydrochloric acid is used to adjust the pH of the formulation to about 6. Adjust to 0 or about 7.4.

[0172] In some embodiments, the formulations described herein are aqueous, i.e., they comprises at least about 90%, at least about 92%, or at least about 95% water.

[0173] Without being bound by theory, the viscosity of the formulations having carbomer homopolymer type B varies with pH. increases as the pH is adjusted from acidic to neutral, but the viscosity decreases with increasing ionic strength. The present inventors have found that the use of tromethamine as a buffer reduces the We found that increasing the pH was accompanied by no substantial increase in the on-state strength. Without being affected by the above, the inventors have found that glycerin increases the osmolarity of the formulation by increasing its ionic strength. It has also been found that glycerin is well tolerated and non-irritating. and also acts as a water retention agent and additional viscosity agent.

[0174] Without being bound to any particular theory, the inventors believe that the surfactant in the formulation The inclusion of the agent also acts as a wetting agent for the compound of formula I, thereby preventing the particles of compound I from becoming wet. 100% water wetting while reducing the potential for irritation and foaming and improving redispersibility of the suspension was found to promote

[0175] In some embodiments, the formulations described herein further comprise additional components. In certain embodiments, the formulation comprises a cyclodextrin derivative, e.g., β-cyclodextrin. In certain embodiments, the cyclodextrin derivatives include cyclodextrin derivatives, γ-cyclodextrin derivatives, or combinations thereof. The cyclodextrin is hydroxypropyl β-cyclodextrin or sulfoalkenyl β-cyclodextrin alkyl ethers. Cyclodextrin derivatives, if present is at least about 1.5 w / v%, at least about 3.0 w / v%, at least about 3.5 w / v% % or at least about 4.5 w / v%, but not more than about 10.0 w / v%, about 8.0% It may be present in an amount of about 5.5% w / v or less, about 6.5% w / v or less, or about 5.5% w / v or less. In certain embodiments, the formulation contains about 5% w / v hydroxypropyl β-cyclodextrin The compounds contain either sulfoalkyl ether β-cyclodextrin or sulfoalkyl ether β-cyclodextrin.

[0176] In some embodiments, the formulations of the invention may include additional therapeutic agents in addition to Compound I. Additional therapeutic agents include, for example, other compounds and antibodies useful for treating ocular surface disorders. A non-exhaustive list of such drugs includes ketorolac, nepafenac, bromocriptine, and bromocriptine. Nonsteroidal anti-inflammatory drugs such as mufenac, corticosteroids; cyclosporine, Medications for dry eye disease such as tetegrast or other TRPV1 inhibitors. In certain embodiments, the additional therapeutic agent is dexamethasone, fluocinolone, lotepred nol, difluprednate, fluorometholone, prednisolone, prednisone, med Lisone, triamcinolone, betamethasone, rimexolone or a pharma- ceutically acceptable salt thereof Further examples of such additional therapeutic agents that may be included in the pharmaceutical composition include ophthalmic steroids. Non-limiting examples include Xiidra® (lifitegrast), Res Tasis® (cyclosporine), minocycline, doxycycline or other Other examples include selenium disulfide, salicylic acid, and keratolytic agents such as acids, glycolic acid, and the like, or pharma- ceutically acceptable salts thereof.

[0177] In some embodiments, the formulation is stored at a refrigerated temperature (e.g., 4°C). In some embodiments, the formulation is allowed to warm to room temperature prior to administration.

[0178] In some embodiments, the suspension is packaged in a single-dose container. In some embodiments, the formulations are packaged in multi-dose containers.

[0179] The formulations described herein may be administered one to six times daily, according to the routine discretion of a skilled clinician. In some embodiments, the formulation is administered 1, 2, 3, or 4 times daily. will be done.

[0180] In some embodiments, the formulation exhibits less than about 10% precipitation after six months of storage at room temperature. In some embodiments, the formulations have a pH of less than about 8%, less than about 7%, or less than about 8% after 6 months of storage at room temperature. %, less than about 6%, less than about 5%, less than about 4%, less than about 3%, or less than about 2% precipitation. The precipitation behavior can be determined by methods commonly known to those skilled in the art, for example as described herein. It is measured thus.

[0181] In some embodiments, the amount of Compound I in the formulation is maintained at refrigerated (e.g., about 4° C.) storage. After about 6 months of administration, the amount is at least 90% of the original amount. The amount of Compound I in the sample was approximately 8 months, 10 months, 12 months, and 15 months after storage under refrigeration. At least about 90% of the original amount after about 18 months or about 18 months. In the form, the amount of Compound I in the formulation is approximately 6 months after storage under refrigeration (e.g., about 4°C). At least about 91%, at least about 92%, at least about 93%, At least about 94%, at least about 95%, at least 96%, at least about 97% or less In some embodiments, the amount of Compound I in the formulation is at least about 98% under refrigeration. At least about 91%, at least about 92%, or at least about 93% of the original amount after about 18 months of storage. at least about 93%, at least about 94%, at least about 95%, at least 96%, The amount of Compound I in the formulation is, for example, about 97% or at least about 98%. C, LC / MS, or other methods commonly known to those skilled in the art.

[0182] In some embodiments, the formulation has less than about 10% degradation products after 6 months under refrigeration. The degradation products were analyzed using a 0.1% trifluoroacetic acid (TFA) water / acetonitrile mobile phase. When analyzed by HPMC using a gradient of 1.23 relative to compound I In some embodiments, the formulation has a shelf life of about 9% or less after 6 months under refrigeration. About 8% or less, about 7% or less, about 6% or less, about 5% or less, about 4% or less, about 3% or less, or about 2% The following degradation products are included:

[0183] In some embodiments, about 10% or less of Compound I in the formulation remains at 40° C. for 12 weeks. In certain embodiments, the amount of Compound I in the formulation is about 9% or less, about 8% or less, Approximately 7% or less, approximately 6% or less, approximately 5% or less, approximately 4% or less, approximately 3% or less, approximately 2% or less at 40℃ Decomposes when stored at room temperature for 12 weeks.

[0184] In some embodiments, the pharmaceutical formulations of the present invention contain an additional therapeutic agent in addition to Compound (I). The additional therapeutic agent may include, for example, other compounds useful for treating ocular surface disorders and A non-limiting list of such agents may include ketorolac, nepafena, nonsteroidal anti-inflammatory drugs such as cyclosporine, bromfenac, and corticosteroids; Medications for dry eye disease include rituximab, lifitegrast, or other TRPV1 inhibitors. In certain embodiments, the additional therapeutic agent is dexamethasone, fluocinolone, lorlatinib, or lorlatinib. Teprednol, difluprednate, fluorometholone, prednisolone, prednisolone medrysone, triamcinolone, betamethasone, rimexolone or its pharma- ceutical acceptable salts Such additional therapeutic agents that may be included in the pharmaceutical composition include ophthalmic steroids, such as salts thereof. Further non-limiting examples of therapeutic agents include Xiidra® (lifitegrast). , Restasis® (cyclosporine), minocycline, doxycycline Other examples include selenium disulfide, Keratolytic agents such as salicylic acid, glycolic acid, and the like, or pharma- ceutically acceptable salts thereof. can be done.

[0185] Method of preparation In some embodiments, the formulation comprises an amount of 4-(7-hydroxy-2-isopropyl -4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or its salt , cocrystals or polymorphs, and surfactants, suspending agents, osmotic agents, buffers, preservatives, salts and The pharmaceutical composition is prepared by mixing the pharmaceutical composition with one or more excipients selected from the group consisting of preservatives.

[0186] In some embodiments, the present invention provides a method of making a pharmaceutical formulation of Compound I. In some embodiments, the formulation comprises an amount of 4-(7-hydroxy-2-isopropyl- 4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or a salt thereof, Cocrystals or polymorphs, Non-ionic surfactants; Suspension agents; Osmotic agents; buffer; salt; Optionally, a preservative; and Mix with water up to 100% qs; and It is prepared by adjusting the pH to the range of about 5.5 to about 8.0.

[0187] In some embodiments, compound I is preserved in water, optionally with a surfactant. In some embodiments, Compound I is added as a storage suspension. In alternative or additional embodiments, the stock suspension of Compound I is present in an amount of 0. In some embodiments, the stock suspension of Compound I further comprises 2% tyloxapol. In some embodiments, the compound I in the formulation is milled to obtain the desired particle size. Compound I D 90 (diameter at which 90% of compound I is made up of smaller particles) is approximately 10 μm less than about 8 μm, less than about 6 μm, less than about 4 μm, less than about 3 μm, or about 2 μm. In some embodiments, the D of Compound I in the formulation 50 (50% of compound I is smaller Diameter (composed of nuclei) is less than about 10 μm, less than about 8 μm, less than about 6 μm, less than about 4 μm , less than about 3 μm, less than about 2 μm, or about 1 μm. In some embodiments, the particle size of the formulation is Compound I D 10 (diameter of particles smaller than 10% of compound I) is approximately 5 μm less than about 4 μm, less than about 3 μm, less than about 2 μm, less than about 1 μm, or about 0.3 μm. do.

[0188] In certain embodiments, the non-ionic surfactants, suspending agents, osmotic agents, buffers and salts are In some embodiments, the formulation is preservative-free.

[0189] An exemplary method for preparation of a 1.5% w / v Compound I suspension is described below. 1. Polybutylene Terephthalate, with PTFE lined cap and magnetic stir bar Tare a clean, dry glass Schott bottle. 2. Add the batch amount of Compound I solvent (including suspending agent, osmotic agent, surfactant and salt, p H adjusted to final pH). Seal and sterilize the compounding vessel with steam (F0 ≥ 30). 3. Transfer the container to a horizontal laminar flow workbench and allow to cool. 4. Aseptically weigh out the batch amount of sterile 10% Compound I / 0.2% surfactant into a compounding vessel. If necessary, add sterile (either steam sterilized or sterile filtered) purified water qs. Adjust to final batch weight and mix until uniform. 5.1.Aseptically fill the 5% suspension into sterile dispensing bottles. Insert the suspension tip and twist to seal. Tighten to seat the tip and seal. 6. Remove the filled unit from the laminar flow workbench and label it. Final pH and Osmolality values ​​are determined.

[0190] How to use Without being bound by theory, blockers of the transient receptor potential vanilloid 1 (TRPV1) It is hypothesized that these compounds may be useful in the treatment of pain, for example chronic pain.

[0191] Thus, in some embodiments, the present invention provides a method for treating ocular surface pain in a subject. The present invention provides a method for treating a chronic inflammatory bowel disease, comprising administering to a patient a therapeutically effective amount of Compound (I) or a pharma- ceutically acceptable salt thereof, a solvent, In some embodiments, the present invention includes administering to a subject a solvate or cocrystal thereof. A method for reducing ocular surface pain in a subject in need thereof is provided, the method comprising administering an effective amount of a compound administering compound (I) or a pharma- ceutically acceptable salt, solvate, or cocrystal thereof to a subject; In some embodiments, the present invention provides a compound according to formula I in treating or reducing ocular surface pain. The present invention provides the use of a compound or a pharma- ceutically acceptable salt, solvate or co-crystal thereof. In some embodiments, the compound of formula I is polymorphic form B. In certain embodiments, the compound of formula I is polymorphic form B. The methods described herein are carried out by administering the formulations of Compound I described above. Thus, the present invention provides a method for treating a patient suffering from atopic dermatitis by administering a formulation of Compound I as described herein. In some embodiments, the method comprises administering to the ocular surface a therapeutic agent to the ocular surface. This results in a reduction in face pain.

[0192] In some embodiments, the subject is suffering from episodic or acute ocular pain. In some embodiments, the subject suffers from chronic ocular surface pain lasting for at least three months. In some embodiments, the subject suffers from chronic ocular surface pain lasting for at least two months. In some embodiments, the subject suffers from chronic ocular surface pain lasting at least one month. In some embodiments, the subject suffers from chronic ocular surface pain lasting at least 4 months. In some embodiments, the subject is diagnosed with chronic ocular surface pain lasting at least 5 months. Thus, in some embodiments, the present invention provides an effective amount of a compound of formula I or a salt, solvate, polymorph, or cocrystal thereof in a subject by administering to the subject In some embodiments, the present invention provides a method for treating chronic ocular surface pain. by administering to a subject an amount of a compound of formula I or a salt, solvate, polymorph, or co-crystal thereof Thus, a method for reducing chronic ocular surface pain in a subject is provided. The use of a compound of formula I or a pharma- ceutically acceptable salt, solvate, polymorph or the like thereof in the treatment of pain. In some embodiments, the compound of formula I is a compound of formula I described herein. It is in the formulation as described.

[0193] In some embodiments, the formulation is administered to the ocular surface of a subject, for example, the cornea, conjunctiva, or conjunctival sac of the eye. The drug is administered to any part of the body.

[0194] In some embodiments, the present invention provides an ophthalmic solution at a concentration of about 0.5% w / v to about 3.5% w / v. The present invention provides for administration of a compound of formula I to a subject in need thereof in a pharmaceutical compatible formulation. In some embodiments, the concentration for administration is about 0.5% w / v to about 3.5% w / v, about 0.5%w / v ~ approx. 2.5%w / v, approx. 0.5%w / v ~ approx. 1.5%w / v, approx. 0.5% w / v ~ approx. 3.0% w / v, approx. 1.0% w / v ~ approx. 2.5% w / v, approx. 1.5% w / v ~ Approximately 3.0% w / v, in the range of approximately 0.5% w / v to approximately 2.5% w / v. In the form, the concentration of Compound I in the ophthalmically compatible formulation is at least about 0.5% w / v, At least about 1.0% w / v, at least about 1.5% w / v, at least about 2.0% w / v or at least about 2.5% w / v. In some embodiments, for topical use The concentration of the compound of formula I in the formulation for 4.0% w / v or less, about 3.5% w / v or less, or about 3.0% w / v or less. In an embodiment, the concentration of the compound of formula I in a formulation for topical use is about 0.5% w / v, Approx. 1.0%w / v, approx. 1.5%w / v, approx. 2.0%w / v, approx. 2.5%w / v, approx. 3.0 % w / v or about 3.5% w / v. In some embodiments, per dose per eye The dose is about 0.15 to about 1.15 mg, or about 0.15 mg, 0.2 mg, or about 0.25 mg. g, approx. 0.3 mg, approx. 0.35 mg, approx. 0.4 mg, approx. 0.45 mg, approx. 0.5 mg, approx. 0.55mg, about 0.6mg, about 0.65mg, about 0.7mg, about 0.75mg, about 0. 8mg, approx. 0.85mg, approx. 0.9mg, approx. 0.95mg, approx. 1.0mg, approx. 1.05m g, about 1.1 mg, or about 1.15 mg. In some embodiments, the dose per eye is The dose per unit is about 0.18 mg, about 0.37 mg, about 0.55 mg, about 0.74 mg or In some embodiments, the total daily dose per eye is about 0. 5 to about 3.5 mg or about 0.5 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 2 In some embodiments, the compound of formula I is The composition is administered to a subject 1-6 times per day, for example, 1, 2, 3, or 4 times per day. In embodiments, the compound of formula I is administered for at least about 1 month, at least about 2 months, or at least In some embodiments, the compound of formula I is administered to the subject for a period of about three months. is also administered to the subject for approximately 12 weeks.

[0195] In some embodiments, the ocular surface pain or chronic ocular surface pain is caused by dry eye disease, shavings, or the like. Glenn's syndrome, conjunctivitis (including keratoconjunctivitis, vernal keratoconjunctivitis, and allergic conjunctivitis), epicorneal Basement membrane dystrophy, Acanthamoeba, Fibromyalgia, Meibomian gland dysfunction, Thyroid Ophthalmopathy, Rosacea, Ptosis, Keratoconus, Ocular Pain Syndrome, Stevens-Johnson Syndrome , corneal epitheliopathy, corneal neuropathy (including LASIK-induced corneal neuropathy), corneal dystrophy corneal dystrophy (including recurrent corneal dystrophy), epithelial basement membrane dystrophy, corneal erosion or corneal abrasions (including recurrent corneal erosions or abrasions), ocular surface diseases, blepharitis, Graft-versus-host disease, meibomianitis, glaucoma, conjunctival laxity, keratopathy (herpetic keratopathy, filiform keratopathy) keratitis (including herpes simplex virus, keratopathy, zona, bullous keratopathy, lagophthalmos, etc.) keratitis), iritis, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, The present invention relates to one or more of the following conditions: patients recovering from neuralgia, xerophthalmia, or neurotrophic keratitis. In some embodiments of the methods described herein, the subject is treated with photorefractive keratectomy (PRK). K) Lasts for at least 3 months after surgery or laser in situ keratomileusis (LASIK) surgery The patient suffers from ocular pain.

[0196] In certain embodiments, the ocular surface pain or chronic ocular surface pain is caused by dry eye disease or shaving. In some embodiments, the subject is diagnosed with conjunctivitis, subconjunctival hemorrhage, Subconjunctival scar, conjunctival membrane, conjunctival ulcer, punctate superficial epithelial erosion, epithelial defect, eyelid margin ulcer, eyelid margin Keratosis, blepharocele, blepharocele, trichiasis, anterior blepharitis, lacrimal punctum obstruction, meibomian gland disease , corneal opacity, dry eye, bilateral eyelashes, limbal stem cell failure, or corneal neovascularization. is.

[0197] In some embodiments, administration of a compound of formula I reduces ocular pain in a subject compared to a placebo. In some embodiments, the reduction in ocular pain in a subject is measured by a VAS score In some embodiments, the serotonin level is at least about 3 compared to placebo when measured above. administration results in a difference of at least about 4, as measured on a VAS score, compared to placebo; At least about 5, at least about 6, at least about 7, at least about 8, at least about 9 or results in a reduction in ocular pain in at least about 10 subjects. In some embodiments, administration is at least about 10%, at least about 15%, at least about 20%, or % or at least about 25% reduction in pain in the subject.

[0198] In some embodiments, administration of the compound of formula I occurs about half an hour after administration, about one hour after administration, or about one hour after administration. After about 2 hours, about 2 hours, or about 2 to 4 hours, the subjects were compared with placebo as measured by VAS scores. In some embodiments, the administration of The administration of the compound of formula I results in a reduction in pain in the subject as measured 7 days after administration. In some embodiments, the administration reduces pain in the subject as measured 14 days after administration of the compound of Formula I. This results in a reduction in pain.

[0199] In some embodiments, the reduction in pain score is measured before and after administration of Compound I to a subject. This results from the difference in pain scores. In some embodiments, pain as measured by VAS The reduction in score results from the difference in pain scores before and after administration of Compound I to the subject. In some embodiments, the reduction in pain score occurs within about 30 minutes after administration of Compound I to the subject. In some embodiments, the reduction in pain score is about 1 hour after administration of Compound I to the subject. , within about 2 hours, about 3 hours, about 4 hours, about 5 hours, or about 6 hours. In one embodiment, the administration results in a reduction in pain in a subject as measured 7 days after administration of a compound of formula I. In some embodiments, the administration is measured 14 days after administration of the compound of formula I. When administered, the administration results in a reduction in pain in the subject.

[0200] In some embodiments, administration of a compound of formula I provides a response to at least one question of the OPAS. an improvement in score of at least about 10%, at least about 20%, or at least about 30% relative to results.

[0201] In some embodiments, administration of a compound of formula I results in at least one visual task questionnaire. At least about 10%, at least about 20%, or at least about 30% of the questions Brings core improvements.

[0202] In some embodiments, administration of a compound of formula I reduces ocular hyperemia (ocular In some embodiments, administration of a compound of formula I results in a reduction in redness and rash. In comparison, it resulted in a reduction in Grade 1, Grade 2, Grade 3, or Grade 4 ocular redness. vinegar.

[0203] In some embodiments, administration provides a dose that is at least about 1, at least about 2, at least about 3, at least about 4, or at least about 5 This results in a reduction in

[0204] Thus, in some embodiments, the present invention provides a method for treating ocular redness in a subject in need thereof. The method of claim 1, further comprising administering to said patient a compound of formula I or a salt, solvate, polymorph or co-form thereof. In some embodiments, the present invention relates to a method for treating a subject comprising administering to the subject an effective amount of a crystalline form of the present invention. The present invention relates to a compound of formula I or a pharma- ceutically acceptable salt, solvate or derivative thereof for use in the treatment of ocular hyperemia. In some embodiments, the administration comprises administering a compound selected from the group consisting of a McMonnies strain stearate and a cocrystal. In kale, at least about 1, at least about 2, at least about 3, at least about 4 or results in a reduction in ocular hyperemia score of at least about 5. In some embodiments, the present invention provides In an ophthalmologically compatible formulation, the concentration is about 0.5% w / v to about 3.5% w / v. In some embodiments, the method for administration of the compound of formula I to a subject is Concentrations are about 0.5% w / v to about 3.5% w / v, about 0.5% w / v to about 2.5% w / v, Approx. 0.5%w / v~Approx. 1.5%w / v, Approx. 0.5%w / v~Approx. 3.0%w / v, Approx. 1.0 %w / v ~ approx. 2.5%w / v, approx. 1.5%w / v ~ approx. 3.0%w / v, approx. 0.5%w / v to about 2.5% w / v. In certain embodiments, in formulations for topical use The concentration of the compound of formula I is about 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2 0.0% w / v, about 2.5% w / v, about 3.0% w / v or about 3.5% w / v. In some embodiments, the dose per administration per eye is about 0.15 to about 1.15 mg or Approx. 0.15mg, 0.2mg, approx. 0.25mg, 0.3mg, approx. 0.35mg, approx. 0.4 mg, about 0.45mg, about 0.5mg, about 0.55mg, about 0.6mg, about 0.65mg , about 0.7mg, about 0.75mg, about 0.8mg, about 0.85mg, about 0.9mg, about 0 0.95 mg, about 1.0 mg, about 1.05 mg, about 1.1 mg or about 1.15 mg. In some embodiments, the dose per administration per eye is about 0.18 mg, about 0.37 mg, or about 0.4 mg. mg, about 0.55 mg, about 0.74 mg, or about 0.92 mg. In this case, the total daily dose per eye is about 0.5 to about 3.5 mg or about 0.5 mg, about 1.0 mg, or about 2.0 mg. mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg or about 3.5 mg. In some embodiments, the compound of formula I is administered 1 to 6 times per day, for example, 1, 2, 3 or 4 times per day. or 4 times to a subject. In some embodiments, the compound of formula I is administered at least about 1 The subject is administered the compound for a period of at least about one month, at least about two months, or at least about three months. In the form of a pharmaceutical agent, the compound of formula I is administered in the formulations described herein.

[0205] In some embodiments, the ocular congestion is caused by dry eye disease, Sjogren's syndrome, conjunctivitis ( keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), corneal epithelial basement membrane dystrophy , Acanthamoeba, fibromyalgia, meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, Keratoconus, Ocular pain syndrome, Stevens-Johnson syndrome, Corneal epitheliopathy, Corneal nerve Disorders (including LASIK-induced corneal neuropathy), corneal dystrophies (recurrent corneal dysplasia) rheumatoid arthritis, epithelial basement membrane dystrophy, corneal erosion or abrasion (recurrent Corneal erosion or abrasion), ocular surface disease, blepharitis, graft-versus-host disease, myocardial infarction, Conjunctivitis, glaucoma, conjunctival laxity, keratopathy (herpetic keratopathy, filamentous keratopathy, band-like or blister-like keratopathy) keratopathy (including lagophthalmos keratopathy), keratitis (including herpes simplex virus keratitis), iris inflammation, episcleritis, corneal surgery, multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia or The present invention relates to a method for treating neurotrophic keratitis, comprising administering to a patient a therapeutically effective amount of the ... In some embodiments, the ocular hyperemia is treated with photorefractive keratectomy (PRK) surgery or laser. Lasts for at least three months after Laser Intracranial Invasive Keratomileusis (LASIK) surgery.

[0206] In some embodiments, the ocular surface pain or chronic ocular surface pain is associated with dry eye disease. In some embodiments, administration of a compound of formula I reduces the symptoms of dry eye disease. Dry eye disease is generally characterized by inflammation of the ocular surface and lacrimal glands and poor tear quality. Dry eye is understood to be a complex, multifactorial condition characterized by a decrease in the amount of blood in the blood. Up to 30% of patients with eye disease are thought to suffer from ocular surface pain, which can be chronic. Thus, in some embodiments, the present invention provides a method for treating dry eye, eye discomfort, eye redness, eye pain, and eye congestion. Dry eye symptoms including one or more of the following: burning or stinging sensation, roughness or foreign body sensation, or photophobia At least about 10%, at least about 15%, at least about 20% or less of the symptoms of the patient also results in a reduction of about 30%.

[0207] In some embodiments, the present invention provides a method for treating dry eye disease in a subject in need thereof. The method comprises administering to a patient an effective amount of a compound of formula I or a salt, solvate, polymorph, or co-crystal thereof. In some embodiments, the present invention relates to a method for treating a subject in need thereof, comprising administering to the subject The method of treating dry eye disease in a subject comprising administering to said subject an effective amount of a compound of formula I or its For a method comprising administering to a subject a salt, solvate, polymorph, or co-crystal of a compound of formula I The mixture may be aged for at least 2 months, at least 3 months, at least 4 months, or at least 5 months. In certain embodiments, the present invention provides a method for treating dry eye disease, comprising administering Use of compounds of formula I or pharma- ceutically acceptable salts, solvates or co-crystals thereof in therapy In some embodiments, the present invention provides a method for treating dry eye, eye discomfort, eye redness, eye pain, and eye discomfort. Dry eye symptoms including one or more of the following: burning or stinging sensation, roughness or foreign body sensation, or photophobia In some embodiments, the present invention provides a method for treating a patient suffering from a disease comprising administering to said patient at least about 10% of said symptoms. In an ophthalmologically compatible formulation at a concentration of about 0.5% w / v to about 3.5% w / v The present invention provides for administration of a compound of formula I to a subject. In some embodiments, the concentration for administration is The concentration is about 0.5% w / v to about 3.5% w / v, about 0.5% w / v to about 2.5% w / v, about 0.5%w / v ~ approx. 1.5%w / v, approx. 0.5%w / v ~ approx. 3.0%w / v, approx. 1.0% w / v ~ approx. 2.5% w / v, approx. 1.5% w / v ~ approx. 3.0% w / v, approx. 0.5% w / v ~ In certain embodiments, the formula in a formulation for topical use is in the range of about 2.5% w / v. The concentrations of compound I are about 0.5% w / v, about 1.0% w / v, about 1.5% w / v, and about 2. 0% w / v, about 2.5% w / v, about 3.0% w / v or about 3.5% w / v. In some embodiments, the dose per administration per eye is about 0.15 to about 1.15 mg or about 0.15mg, 0.2mg, approx. 0.25mg, 0.3mg, approx. 0.35mg, approx. 0.4m g, about 0.45mg, about 0.5mg, about 0.55mg, about 0.6mg, about 0.65mg, Approximately 0.7mg, approximately 0.75mg, approximately 0.8mg, approximately 0.85mg, approximately 0.9mg, approximately 0. 95 mg, about 1.0 mg, about 1.05 mg, about 1.1 mg, or about 1.15 mg. In some embodiments, the dose per administration per eye is about 0.18 mg, about 0.37 mg, or about 0.5 mg. g, about 0.55 mg, about 0.74 mg, or about 0.92 mg. The total daily dose per eye is about 0.5 to about 3.5 mg or about 0.5 mg to about 1.0 mg. g, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, or about 3.5 mg. In some embodiments, the compound of formula I is administered 1 to 6 times per day, for example, 1, 2, 3 or 4 times per day. In some embodiments, the compound of formula I is administered to the subject four times. The subject is administered the compound for a period of at least about one month, at least about two months, or at least about three months. In embodiments, the compound of formula I is administered in a formulation as described herein.

[0208] In some embodiments of the methods described herein, the administration of a compound of formula I is Compared with the 10-year-old boy, best corrected visual acuity, slit-lamp biomicroscopy, mydriatic examination, blink rate, and tear production were significantly improved. does not result in a change in one or more of the following: , less than 4% difference, or less than 3% difference). It has been found that administration of a compound of formula I improves wound healing in patients in need thereof compared to placebo. This does not cause delays in

[0209] Patient population In certain embodiments, the subject to be treated by the methods described herein is , suffering from an ocular surface disorder. Non-limiting examples of ocular surface disorders include chronic ocular surface pain (COS) and chronic ocular surface pain (COS). OSP), dry eye disease, Sjogren's syndrome, conjunctivitis (keratoconjunctivitis, vernal keratoconjunctivitis, allergic conjunctivitis), corneal epithelial basement membrane dystrophy, Acanthamoeba, fibromuscular pain, meibomian gland dysfunction, thyroid eye disease, rosacea, ptosis, keratoconus, ocular pain syndrome, Stevens-Johnson syndrome, corneal epitheliopathy, corneal neuropathy (LASIK-induced corneal neuropathy), corneal dystrophies (including recurrent corneal dystrophies), epithelial basal Membrane dystrophy, corneal erosion or abrasion (recurrent corneal erosion or abrasion (including wounds), ocular surface disease, blepharitis, graft-versus-host disease, meibomianitis, glaucoma, conjunctival laxity keratopathy (including herpetic keratopathy, filamentous keratopathy, band or bullous keratopathy, and lagophthalmos keratopathy) keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, Recovering from idiopathic sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia or neurotrophic keratitis In some embodiments, the subject is a patient undergoing laser photorefractive keratectomy. At least 3 months after PRK or LASIK surgery The patient has suffered from persistent eye pain for many years.

[0210] In certain embodiments, the methods provided herein are directed to treating ocular surface pain, such as acute ocular surface pain. The present invention is intended to treat or reduce the

[0211] In certain embodiments, the methods provided herein are directed to treating chronic ocular surface pain (COSP), etc. In certain embodiments, the COSP is Persistent symptoms that may distract or interfere with normal daily activities The condition is characterized as persistent ocular surface pain (e.g., persistent severe ocular surface pain). In some cases, COSP may result in an inadequate quality of life and persists for at least 1 month. At least 2 months, at least 3 months, at least 4 months, at least 5 months or less In some embodiments, the COSP lasts for at least about 2 months or at least about 6 months. In other embodiments, the COSP may last for at least about 3 months. In certain embodiments, subjects with COSP may have symptoms that persist for at least four months. For a certain disease (e.g., ocular surface disorders such as dry eye disease or Sjögren's syndrome) Symptoms persist despite compliance with other therapy as indicated.

[0212] In some embodiments, the subject to be treated is a patient suffering from ocular neuropathic pain (ONP). ONP is an ocular disorder that may result from an injury or disease affecting the nerves, e.g., the corneal nerves. ONP is a group of disorders that cause pain in the eyes. Symptoms of ONP include eye pain, sensitivity to light, hyperalgesia or dry eyes. Abnormal sensations (paresthesia) such as dryness, tingling, or a foreign body sensation, in response to stimuli that normally do not cause pain This may include a disorder of the pain caused by the schizophrenia (allodynia). Pain medications may be used to dull the sensation of sensory nerve stimuli or nerve stimuli.

[0213] In some embodiments, the subject to be treated is suffering from lagophthalmos. EK is damage to the cornea that primarily results from prolonged exposure of the ocular surface to the external environment. EK can result in permanent vision loss from ulcers, microbial keratitis, and scarring. Patients at risk for K include those with incomplete eyelid closure (e.g., lagophthalmos, exophthalmos, lid closure) position of the eye), insufficient blink reflex, insufficient blink rate (e.g., neurological disorders, e.g., Parkinson's disease, caused by neuromuscular diseases) and / or the protective lubrication of the cornea Patients with conditions that impair the cornea's ability to protect itself, either through Symptoms of EK include a foreign body sensation, burning sensation, increased tearing, and intermittent blurred vision (unstable vision). Symptoms include dry eye (caused by poor tear film), pain, and photophobia. Standard treatment is a nighttime lubricating ointment. Frequent use of artificial tears and punctal plugs.

[0214] In some embodiments, the subject to be treated is suffering from keratoconjunctivitis. Conjunctivitis is an inflammatory process involving both the conjunctiva and the cornea. Inflammation of the superficial layers of the cornea (keratitis) It commonly occurs, for example, in association with viral and bacterial conjunctivitis in adults. The following types of conjunctivitis are distinguished based on the underlying cause of the inflammation: Keratoconjunctivitis sicca is caused by inflammation resulting from dryness; · Vernal keratoconjunctivitis (VKC) is seasonal and thought to be allergen-induced; Atopic keratoconjunctivitis is one manifestation of atopy; Epidemic keratoconjunctivitis or adenoviral keratoconjunctivitis is caused by adenovirus infection. Rubbed; Infectious bovine keratoconjunctivitis (IBK) is caused by the bacterium Moraxella bovis. bovis, a disease that affects cattle; Pink eye in sheep and goats is mainly caused by Chlamydophila pecorum. dophila pecorum); · Superior limbic keratoconjunctivitis is thought to be caused by structural trauma; Keratoconjunctivitis Electric ophthalmia (Arc Eye) refers to inflammation caused by photoconductive UV light. Taste.

[0215] In some embodiments, the subject to be treated is suffering from dry eye. As used herein, the term "dry eye" refers to insufficient tear production and / or abnormal tear production. Dry eye syndrome, keratoconjunctivitis sicca or keratitis sicca, or tear dysfunction Dry eye syndrome (DEDS), also known as dry eye syndrome or burning eye syndrome, is a condition characterized by dry eye. Dry eye is characterized by a loss of tear film homeostasis. Discomfort due to potential damage to the ocular surface with accompanying ocular symptoms, visual disturbances, tear film instability It is a multifactorial disorder of the tears and ocular surface that results in a range of clinical symptoms, including tear film instability and hypercalcaemia. Osmotic pressure, ocular surface inflammation and injury, and neuroparesthesia play a pathogenetic role. (Craig JP,et al.,The Ocular Surface 2017 ;15:276-83). It is accompanied by increased tear film osmolality and inflammation of the ocular surface. Dry eye disorder can range from mild to moderate to severe. Symptoms of Lyme syndrome include roughness, foreign body sensation, burning sensation, photophobia and decreased vision. Tearing, stinging, itching, gritty or rough feeling, eye discharge, frequent blinking, pus or crust on eyelashes redness, blurred or oscillating vision (usually worse when waking up), (worsened when watching television, driving or playing video games), photosensitivity, eye pain and / or Other symptoms include headaches, eyelid heaviness, and eye strain. Causes of dry eye disease include: These include, but are not limited to: unknown cause, congenital anlacrimation, xerophthalmia, tear Gland resection and sensory denervation; rheumatoid arthritis, Wegener's granulomatosis and systemic lupus erythematosus collagen vascular disease including vascular degeneration; Sjogren's syndrome and autoimmune diseases associated with Sjogren's syndrome Immune disorders; lipid tear film abnormalities caused by blepharitis or rosacea; Vitamin A deficiency Mucinous tear film abnormalities caused by trachoma, diphtheria keratoconjunctivitis, skin mucosa membrane disorder; aging; menopause; and diabetes. Dry eye symptoms as defined herein and and / or symptoms may be precipitated by other conditions, including but not limited to: Possible causes: visual work for long periods of time; computer work; exposure to dry environments; hot air or cold air or air currents; seasonal changes; eye irritation; contact lenses, LASIK and others refractive surgery; fatigue; and isotretinoin, sedatives, diuretics, tricyclic antidepressants, antihypertensives Medicines, oral contraceptives, antihistamines, nasal decongestants, beta-blockers, phenothiazines, atothiazines, Drugs such as pain relieving opiates such as morphine and morphine.

[0216] Diagnostic tests for dry eye include, for example, the cotton swab or, more specifically, the Cochet- Assessment of corneal sensation using a Bonnet aesthesiometer (corneal hypersensitivity and / or hyposensitivity were evaluated) may be present in severe and chronic dry eye disease); e.g., preservative-free Fluorescein-impregnated strips or fluorescein drops moistened with saline solution were used. Measurement of tear film breakup time using a more objective computerized method that does not require For example, staining of the ocular surface with sodium fluorescein, rose bengal, or lissamine green Performing the Schirmer test (relatively insensitive for patients with mild dry eye) ); test for delayed tear clearance; tear meniscus height; measurement of MMP-9 levels MMP-9 has been shown to be elevated in the tears of patients with dry eye disease. and levels correlate with test results in patients with moderate to severe dry eye) ;Measurement of tear osmolality and tear film interferometry;Performance of Sjo test ( Serum SS-A (anti-Ro) and SS-B (anti-La) antibodies, salivary gland protein 1 (SP- 1), carbonic anhydrase 6 (CA6) and parotid secretory protein (PSP), SP-1, CA 6 and PSP detection).

[0217] Artificial tears, lubricating ointments, corticosteroids (e.g., loteprednol 0.4 times daily) Prescription medications include cyclosporine, rifabutin, and cyclosporine. Fitegrast, diquafosol, levamepidol, corticosteroids (e.g., four times a day) Loteprednol 0.5% eye drops.

[0218] The term "tear film dysfunction" refers to when the tear film is disrupted at different locations on the cornea and conjunctiva. This condition causes not only symptoms of irritation, but also unstable and intermittent fluctuations in vision. For example, dry eye syndrome is characterized by tear film dysfunction. Symptoms include tearing, burning, stinging, itching, a gritty or rough feeling, tingling or itching. symptoms include foreign body sensation, eye discharge, frequent blinking, pus or crusting of the eyelashes (usually worse when waking up), Redness, blurred or trembling vision (when reading, using a computer, watching television, driving or playing video games) Symptoms include: sensitivity to light, eye pain and / or headache, heavy eyelids, and eye strain. Can be obtained.

[0219] Adenoviral keratoconjunctivitis, also known as epidemic keratoconjunctivitis, is a common and highly contagious Adenoviral keratoconjunctivitis is a viral infection of the eye. The clinical course of adenoviral keratoconjunctivitis involves the cornea. It is divided into an acute stage with various degrees of conjunctival inflammation with or without corneal opacity and a chronic stage with corneal opacity. can be done.

[0220] Vernal keratoconjunctivitis (VKC) is characterized by severe itching, photophobia, foreign body sensation, and mucoid discharge from the eye ("sticky" blepharospasm, ocular palsy, characterized by symptoms of blepharospasm and blurred vision It is an atopic condition of the outer surface (Buckley, RJ, Int Ophthalm ol Clin,1988 28(4):p.303-8;Kumar,S.,Acta Ophthalmologica, 2009.87(2):p.133-147). It is usually bilateral, but may be asymmetric in nature. It typically affects young males in dry climates; 23% of patients have a perennial form. (Kumar, S., Acta Ophthalmologica, 2009. 87(2):p.133-147;Bonini,S.,et al.,Ophthal biology, 2000.107(6):p.1157-63).

[0221] The manifestations of VKC can be divided into conjunctival, limbal and corneal manifestations: Conjunctival signs include diffuse conjunctival hyperemia and discrete upper tarsal lesions measuring more than 1 mm in diameter. Giant papillae are mentioned; Limbal signs include thickening and opacification of the limbal conjunctiva and the appearance and occasional appearance of gelatinous material. The peripheral limbal Horner-Trantas points are Localized limbal white spots consisting of degenerated epithelial cells and eosinophils (Buckley, R .J.,Int Ophthalmol Clin,1988 28(4):p.303 -8); Corneal manifestations vary depending on the severity of the disease process and may include large erosions, corneal ulcers and scarring. (Buckley, RJ, Int Ophthalmol Clin, 19 88 28(4):p.303-8).

[0222] Patients with active VKC (photophobia, papilla on the superior tarsal conjunctiva, or clearly visible corneal limbus on examination) ocular discomfort (defined as moderate to severe ocular discomfort including Horner-Trantas points) showed a marked increase in symptoms and signs of superficial disease. Patients with inactive VKC (asymptomatic or Mild discomfort and no corneal abnormalities during testing) were not associated with photophobia, conjunctival rhinitis, or Increase in the samine green staining and Schirmer test values ​​and the fluorescein breakdown time (B The syndrome was associated with decreased tear film stability, epithelial cell integrity, and corneal sensitivity. Abnormalities in the function of the corneal nerve and corneal nerve were observed at all stages (progression and resting state). It appears that the ocular surface is affected by the ne(Baltimore).2015 Oct;94(42):e1648).

[0223] The following factors are thought to play a role in VKC: IgE released from mast cells; activated eosinophils; by leukocytes, monocytes and neutrophils and immune regulators such as IL-4, IL-5 and bFGF. The response is mediated through CD4 T-helper-2-driven IV hypersensitivity (Buckl ey,RJ,Int Ophthalmol Clin,1988 28(4):p .303-8;Kumar,S.,Acta Ophthalmologica,200 9.87(2):p.133-147;La Rosa,M.,et al.,Ital J Pediatr,2013.39:p.18).

[0224] Treatment consists of cold compresses and irrigation of the eyelids, saline eye drops, topical antihistamines, Nonsteroidal anti-inflammatory drugs or corticosteroids, e.g., low-absorption corticosteroids ( Fluorometholone, loteprednol, rimexolone, etc.), local mast cell stabilizers ( lomolyn sodium, nedocromil sodium and lodoxamide), topical cyclosporine -A or tacrolimus may help relieve symptoms. and E.Toker,Cornea,2013.32(8):p.1149-54; Vichyanond, P. and P. Kosrirukvongs, Curr Al. lergy Asthma Rep,2013.13(3):p.308-14;Bar ot,RK et al.,J Clin Diagn Res.2016 Jun;1 0(6):NC05-9;Wan Q et al., Ophthalmic Res. Please see 2018;59(3):126-134.

[0225] Atopic keratoconjunctivitis (AKC) usually develops before age 10, whereas VKC usually develops between ages 20 and 30. The age of onset is 50 years older. Conjunctival involvement is classically seen in VKC, with the upper tarsal plate and A In KC, it occurs at the lower tarsal plate. AKC is usually more chronic in nature and more commonly occurs at the cornea. It causes membranous and conjunctival scarring.

[0226] Sjögren's syndrome (Sjögren's syndrome with dry eye) is a condition that often causes severe dry eye. Characterized by dysfunction of exocrine glands, including the salivary and lacrimal glands, causing rheumatoid arthritis It is a chronic inflammatory disorder. The main symptoms are dry eye (keratitis sicca or keratoconjunctivitis sicca) and Severe dry eye can lead to corneal pain, scarring, ulcers, infection, and The differential diagnosis is adult blepharitis, dry eye disease, and juvenile blepharitis. Arthritis of unknown etiology, uveitis, and keratopathy, e.g., superficial punctate keratopathy, fibrous keratopathy Sjögren's syndrome includes conditions such as keratopathy, neuropathic keratopathy, and lagophthalmos. To maintain the integrity of the tear film by preserving, enhancing and / or replenishing insufficient tear secretion Therefore, treatment for Sjögren's syndrome includes artificial tears and lubricating ointments; Autologous serum eye drops; oral omega-6 essential fatty acids; fluid- and gas-permeable scleral lenses; topical corticosteroids; punctal occlusion to reduce tear drainage; small lateral tarsorrhaphy surgery; humidification of environment; hydrophilic bandage lens; bromhexine and 3-isobutyl-1-methyl Tiruxanthine (IBMX) (increases tear production / secretion); a drug that stimulates muscarinic receptors agents (pilocarpine and cevimeline); immunosuppressants, e.g., methotrexate, antimalarials; anti-inflammatory drugs, cyclophosphamide, leflunomide or tumor necrosis factor (TNF), e.g. Liximab, a monoclonal antibody against TNF-alpha; cyclosporine A; Examples of such contact lenses include:

[0227] Stevens-Johnson syndrome (SJS) is a skin emergency or a rash affecting one entire surface area of ​​the skin. One type is characterized by the presence of vesicular lesions of the epithelium and mucosa that involve less than 0.0% of the It is a severe skin reaction. Early symptoms of SJS include fever and flu-like symptoms. This may precede or occur simultaneously with the development of a macular rash involving the torso and face. As the skin grows, the patches gather and the involved areas develop into blisters, eventually resulting in loss of the epithelial layer. During the acute phase of SJS-TEN, 80% of patients will have ocular complications. .

[0228] High fever (>102.2), fatigue, joint pain, macular rash involving the body, neck and face, and new medications A constellation of recent history of exposure to a substance or recent dose increase of current medication is the indicator used to diagnose SJS. A skin biopsy of the affected area is required to confirm the diagnosis. Granulysin can be used as a marker for the diagnosis of SJS. Granulysin levels in blister fluid correlate with the severity of acute SJS (C hung WH,et al.Nat Med.2008;14(12):1343-5 0).

[0229] Eye symptoms in SJS include conjunctivitis, subconjunctival hemorrhage, subconjunctival scarring, conjunctival membranes, and conjunctival Ulcer, punctate superficial epithelial erosion, epithelial defect, eyelid margin ulcer, eyelid margin keratinization, blepharocele, eyelid adhesion, Trichiasis, anterior blepharitis, lacrimal punctum obstruction, meibomian gland disease, corneal opacification, dry eye These include corneal hyperplasia, limbal stem cell failure, and corneal neovascularization. The artificial tears are saline eye drops, preservative-free artificial tears, and other solutions that provide adequate lubrication and irritation to the epithelium. Patients with any corneal or conjunctival epithelial defects should be treated with prophylactic Treated with topical antibiotics, such as fourth-generation fluoroquinolones. Mild or moderate ocular Complications (less than one-third of eyelid margin complications, conjunctival defects less than 1 cm in maximum diameter, and corneal epithelial defects less than 1 cm in maximum diameter) Patients with glaucoma (no deficiency) are usually treated with topical moxifloxacin 0.5% four times a day, or topical moxifloxacin 0.5% twice a day. of cyclosporine 0.05% and topical steroids (prednisolone acetate 4-8 times daily) Treated with dexamethasone 0.1% or twice daily. Severe or very severe Ocular complications (lid margin involvement exceeding one-third, conjunctival defects exceeding 1 cm, and corneal epithelial defects) Patients with BRCA1 / BRCA2 deficiency undergo amniotic membrane (AM) transplantation in addition to the above treatment.

[0230] In some embodiments, the subject to be treated is suffering from corneal epitheliopathy. Corneal epitheliopathy is a condition involving the corneal epithelium that manifests itself in alterations of the corneal epithelial barrier function. It is a disease that occurs

[0231] In some embodiments, the subject to be treated is a patient suffering from corneal neuropathy or corneal neuralgia. Corneal neuropathy or corneal neuralgia is caused by the loss of nerve and sensory fibers in the cornea. It is a disorder involving corneal pain caused by injury. One example of corneal neuropathy is LA SIK-induced corneal neuropathy. Corneal neuropathy is generally diagnosed by dry eye testing. Although the causes and risk factors are still unclear, dry eye-like symptoms, Patients with increased corneal sensitivity and changes in corneal nerve morphology, but without signs of dryness, may have corneal nerve dysfunction. May suffer from menstrual disorders.

[0232] In some embodiments, the subject to be treated is suffering from an ocular surface disease or disorder. The term "ocular surface disease" or "ocular surface disorder" refers to abnormal ocular lid anatomy or function. This can be caused by a variety of abnormalities, including abnormal or altered tear production or composition and associated asymptomatic manifestations. Many diseases can cause ocular surface disorders. Patients with surface lesions may present with clinical signs common to several diseases and may be chronic. punctate keratopathy, filamentous keratopathy, recurrent corneal erosion, bacterial conjunctivitis, culture-negative conjunctivitis, cicatricial conjunctivitis May include adult (cicatricial) conjunctivitis, persistent epithelial defects, infectious keratitis, corneal melting, and ocular surface failure The most common ocular surface disorders are tear film abnormalities and / or dysfunction of the glands in the eyelids ("blepharitis"). ) comes from

[0233] In some embodiments, the subject to be treated is a patient suffering from neurotrophic keratitis or neurotrophic keratitis. Neurotrophic keratopathy (NK) is a condition that affects the cornea. It is a degenerative corneal disease characterized by reduced or absent corneal sensitivity. Corneal innervation via the cornea is impaired. Corneal sensory innervation is impaired in NK. Patients usually do not complain of ocular surface symptoms. However, blurred vision may be due to irregular epithelium or epithelial defects. NK may be reported due to primary edema (PED), scarring, or edema. Stage II NK is the most common. Stage II is defined by recurrent or persistent epithelial defects in the upper half of the cornea. One treatment that can be used in NK involves topical nerve growth factor. Patients usually Due to remodeling of the retina, patients experience pain during treatment with NGF.

[0234] In some embodiments, the subject to be treated is suffering from blepharitis. Eyelid inflammation is an inflammatory condition of the eyelid margin that manifests as persistent changes or superficial keratopathy in the eyelid margin. This can cause vision loss, corneal neovascularization and ulceration. Therefore, blepharitis can be divided into anterior and posterior. Anterior blepharitis affects the eyelid skin, the base of the eyelashes and the eyelids. It affects the eyelash follicles and includes the traditional classification of staphylococcal and seborrheic blepharitis. It affects the meibomian glands and their orifices, and the primary cause is meibomian gland dysfunction. Symptoms of blepharitis include redness, burning sensation, irritation, tearing, eyelid crusting and sticking, and visual disturbances such as photophobia and blurred vision. Long-term symptom management involves a daily eyelid washing routine and prevention of infection and inflammation. Treatments may include the use of therapeutic agents that reduce the oral antibiotics, such as tetracycline antibiotics; Biological substances (tetracycline, doxycycline, minocycline) or macrolide antibiotics Biologics (erythromycin, azithromycin); topical steroids, e.g., corticosteroids Steroids, eg, loteprednol etabonate, fluorometholone; tobramycin / Antibiotics such as dexamethasone or tobramycin / loteprednol and corticosteroids topical combinations of cyclosporine and cyclosporine 0.05%.

[0235] In some embodiments, the subject to be treated is suffering from meibomian gland dysfunction. The meibomian glands are involved in the production of meibum, an oily substance that prevents evaporation of the eye's tear film. It is a holocrine exocrine gland located in the peripheral area of ​​the eyelid inside the tarsal plate. Meibomian gland dysfunction (MGD), also known as blepharitis or inflammation of the meibomian glands, is a Myopathy is generally characterized by terminal duct obstruction and / or qualitative / quantitative changes in glandular secretions. It is a chronic diffuse abnormality of the Baumian gland (Nelson JD, et al., Inve st Ophthalmol Vis Sci 2011;52:1930-7). can cause alterations of the tear film, eye irritation, clinically significant inflammation and ocular surface disease. D often causes dry eyes and can contribute to blepharitis. In addition, topical steroids and topical / oral antibiotics are also prescribed to reduce inflammation. Intense Pulsed Light (IPL) therapy or other devices that apply heat and pressure to activate the glands Mechanical treatments (e.g., LipiFlow) reduce inflammation and improve glandular function in patients. It has also been shown to be beneficial.

[0236] In some embodiments, the subject to be treated is suffering from graft-versus-host disease. Graft-versus-host disease (GVHD) is an inflammatory disease that is unique to allogeneic transplants. Even if the donor and recipient have identical HLA, Acute graft-versus-host disease usually occurs within the first three It develops over a period of months and may involve the skin, intestine, or liver. Steroids are the standard treatment. Chronic graft-versus-host disease may also develop after allogeneic transplantation. In addition to inflammation, chronic graft-versus-host disease is a major cause of late complications. It may cause the development of fibrosis or scar tissue, similar to other autoimmune diseases, and may be functional. It may result in disability and the need for long-term immunosuppressive therapy.

[0237] In some embodiments, the subject to be treated is afflicted with ocular graft-versus-host disease. GVHD occurs in patients who have undergone allogeneic blood stem cell transplantation. It may occur in patients with chronic or chronic GVHD, but Approximately 40-90% of patients with chronic GVHD have ocular Ocular symptoms include moderate to severe keratoconjunctivitis sicca, bilateral peripheral keratoconjunctivitis, and Treatment may include ocular ocular inflammation, ocular ocular inflammation, anterior uveitis, corneal ulcers, or neovascularization. topical lubricants, including artificial tears, autologous serum tears and other topical and systemic immunosuppressive treatments; Sex steroids; topical cyclosporine 0.5%. EXAMPLES

[0238] The following examples are included to demonstrate non-limiting embodiments of the invention.

[0239] General Test Conditions The following procedures were utilized under each test condition.

[0240] Equilibration with solvent at 25°C For equilibration at 25°C, approximately 50 mg of compound I was added to a water bath at 25°C ± 0.1°C, and 1 ml The solution was filtered and air dried for 10 minutes. The components were examined by XRPD (X-ray powder diffraction). If differences were observed, further examination was indicated. Appropriate measurements were performed (e.g., DSC, TG, IR, SEM).

[0241] Equilibration with solvent at 50°C For equilibration with a solvent at 50°C, approximately 50 mg of compound I was placed in a water bath at 50°C ± 0.1°C. The solution was equilibrated with 1 ml of solvent for 24 hours. The filtrate was used as described in the specific examples. .

[0242] Crystallization from hot saturated solutions To crystallize compound I from a hot saturated solution, approximately 300 mg of the drug substance was added to a minimum amount of solvent at 60°C. The solution was dissolved in a solvent and filtered hot. No remaining crystals were visible. The solution was placed in an ice bath and stirred. The precipitate was collected on a filter, dried, and examined as above. It can be modified as described in the examples.

[0243] Precipitation by addition of solvent In the case of precipitation of compound I by addition of a solvent, compound I is dissolved in a solvent in which it is highly soluble. Then, a solvent in which Compound I is highly insoluble was added. The precipitate was treated as described in the specific examples. did.

[0244] X-ray diffraction The X-ray powder diffraction (XRPD) patterns described herein were analyzed using CuK α Using radiation, Br The XRPD patterns were recorded on a Kerker D8 Advance diffractometer. (2θ) was recorded between

[0245] Those skilled in the art will appreciate that X-ray diffraction patterns are obtained with measurement errors that depend on the measurement conditions used. In particular, it will be appreciated that intensities in an X-ray diffraction pattern may be used. It is generally known that the intensity may increase or decrease depending on the measurement conditions. Relative intensity is also used. It should be further understood that this may vary depending on the experimental conditions and the wavelength of the X-ray radiation. The agreement in 2θ diffraction angles between the sample and the reference is 0.2 for the same crystal form. 3°, and such a measurement error should be considered as being related to the above-mentioned diffraction angle. As a result, the crystalline forms of the present invention are consistent with the X-ray diffraction patterns depicted in the attached drawings disclosed herein. It is understood that the present invention is not limited to crystal forms that provide exactly the same X-ray diffraction pattern as the pattern. The X-ray diffraction pattern should be substantially the same as that shown in the attached drawing. Any of the crystalline forms provided are within the scope of the present invention. The ability to ascertain the gender is within the skill of one in the art.

[0246] thermogravimetric method The TGA instrument used to test the crystal morphology was a Metter TGA851e T The sample was 10 to 20 milligrams and heated at temperatures between 30°C and approximately 300°C. The analysis was performed at a heating rate of 20° C. / min within a temperature range.

[0247] Differential Scanning Calorimetry (DSC) The DSC instrument used to examine the crystal morphology was a Mettler DSC822e or The DSC cell / sample chamber was a Perkin Elmer DSC7. The instrument was purged with ultra-high purity nitrogen gas at 20-50 ml / min. The instrument was calibrated with high purity indium. Samples were placed in open aluminum DSC pans and measured against an empty reference pan. Approximately 1-3 mg of sample powder was placed on the bottom of the pan and gently tapped to separate it from the pan. The weight of the sample was measured accurately and recorded to the nearest hundredth of a milligram. The temperature range was programmed to heat at 10°C / min between 30°C and 300°C. Ta.

[0248] Example 1. Preparation of Crystalline Form A Crystalline Form A was obtained by converting the hydrochloride salt of Compound I into the free base. Crystallization was carried out by cooling hot methanol to 0° C., where the compound was identified as crystalline form A. It was crystallized.

[0249] The differential scanning calorimetry curve for crystalline form A shows a small endothermic event at about 264° C. followed by It showed a melting point of about 269° C. Figure 1 shows the simulated and measured X-ray diffraction patterns of crystalline form A. The X-ray powder diffraction pattern of crystalline form A is shown in FIG. The single crystal data for crystalline form A of compound I are as follows: This is: Molecular formula:C 18 H 15 N3O2 Molecular weight (free acid): 305.34 Lattice parameters: Space symmetry Monoclinic space group P21 / n Cell volume (Å 3 ) 3157.2 Crystal density (g / cm 3 ) 1.285 a(Å) 16.285 b(Å) 7.977 c(Å) 24.640 β(°) 99.046 z8

[0250] [Table 1]

[0251] Example 2. Preparation of Crystalline Form C Crystalline form C can be prepared by heating crystalline form A to about 250° C. in a thermogravimetric analyzer or by precipitation. Crystal form B was obtained by heating at 250° C. for 80 minutes. 1:1 mixture with crystal form B In the present study, crystalline form C was converted to crystalline form B with isopropanol. In a 1:1 mixture, crystalline form C was dissolved in methanol to form the solvate S B (Crystal form G) Ta.

[0252] FIG. 3 shows an overlay of the simulated and measured X-ray diffraction patterns of crystalline form C. The X-ray powder diffraction pattern of Form C is shown in FIG. 4, and the peak list is shown in Table 2. The lattice parameters for morphology C are: Spatial symmetry Orthorhombic space group Pna21 Cell volume (Å 3 ) 3078.3 Crystal density (g / cm 3 ) 1.318 a(Å) 15.685 b(Å) 8.281 c(Å) 23.697 z8

[0253] [Table 2]

[0254] Example 3. Preparation of Crystalline Form E Approximately 1000 mg of compound I in polymorphic form B was dissolved in 20 ml of acetone / mL at 25° C. for 1 week. The solid was equilibrated with a mixture of water (1:1) and then filtered. XRPD analysis of the recovered solid showed and modified H A (hydrate form) pattern was observed. Approximately 1000 mg of hydrate H A , 2 After heating in an oven at 60° C. for about 16 minutes, crystalline form E was obtained.

[0255] [Table 3]

[0256] [Table 4]

[0257] Crystalline form E was found to be non-hygroscopic. The maximum water uptake was up to 92% of the phase. Humidity is less than 0.1% at 25°C.

[0258] Crystalline form E exhibited an onset melting temperature of about 281° C. as measured by DSC. As can be seen, crystalline form E converts to crystalline form B when equilibrated with ethanol. The solubility of crystalline form E was measured at 25° C. The analysis was performed by HPLC and the results are shown in Table 5. show.

[0259] [Table 5]

[0260] FIG. 5 shows an overlay of the simulated and measured X-ray diffraction patterns of crystalline form E. The X-ray powder diffraction pattern of Form E is shown in FIG. 6, and the peak list is shown in Table 6. The lattice parameters for crystal form E are: Spatial symmetry Triclinic space group P-1 Cell volume (Å 3 ) 1637.8 Crystal density (g / cm 3 ) 1.238 a(Å) 8.592 b(Å) 13.046 c(Å) 14.935 α(Å) 90.34 β(Å) 90.23 γ(Å) 78.03 z4

[0261] [Table 6]

[0262] Example 4. Crystalline Form F (Hydrate H A Preparation of Hydrate H A (Crystal form F) is the crystalline form A or crystalline form C in acetone / water (1:1) at 25°C. The DSC curve was obtained by equilibration of a slurry of crystalline form B. The DSC curve shows a dip of about 89° C. due to evaporation of water. It shows a broad endotherm at 264 °C followed by several endothermic transitions above 264 °C. Single crystal analysis This confirms the presence of 1 mole of water in the crystal structure (calculated water content is 5.6%). It was acknowledged.

[0263] The X-ray powder diffraction pattern of crystalline form F is shown in FIG. 7, and the peak list is shown in Table 7. do.

[0264] [Table 7]

[0265] Example 5. Crystalline Form G of Compound I (Methanol Solvate S B Preparation of Methanol solvate S of compound I B (Crystal form G) is a crystalline form in methanol at 25°C. It was obtained by equilibration of a slurry of Form A. According to single crystal structure analysis carried out at 100 K, TGA analysis of the sample showed the presence of 1 mole of methanol, up to 0.2%. The amount of residual solvent (calculated methanol content is 9.5% for the monosolvate) was 1.0%. Therefore, the solvent evaporates easily.

[0266] FIG. 8 shows the overlay of the simulated and measured X-ray diffraction patterns of crystalline form G. The X-ray powder diffraction pattern of Form G is shown in FIG. 9, and the peak list is shown in Table 8. The lattice parameters for morphology G are: Spatial symmetry Triclinic space group P-1 Cell volume (Å 3 ) 1849.3 Crystal density (g / cm 3 ) 1.212 a(Å) 8.242 b(Å) 14.478 c(Å) 16.064 α(Å) 80.49 β(Å) 78.33 γ(Å) 85.18 z4

[0267] [Table 8]

[0268] Example 6. Crystalline Form J of Compound I (Acetonitrile Solvate S A Preparation of Acetonitrile solvate S of compound I A (Crystal form J) is dissolved in acetonitrile at 25 °C. The compound was obtained by equilibration of a slurry of crystalline form A of 1,2-dichloro-1,2,3-tetrahydrofuran (1,2,3,4-tetramethyl-2,4-hexanediol). Single crystal analysis revealed that the crystalline structure The presence of 1 mole of acetonitrile (calculated acetonitrile content is 11.9%) was shown.

[0269] The X-ray powder diffraction pattern of crystalline form J is shown in FIG. 10, and the peak list is shown in Table 9. The lattice parameters for crystal form J are: Space symmetry Monoclinic space group P21 / n Cell volume (Å 3 ) 1833.5 Crystal density (g / cm 3 ) 1.255 a(Å) 15.545 b(Å) 5.770 c(Å) 21.348 β(°) 106.75 z4

[0270] [Table 9]

[0271] Example 7. Preparation of Crystalline Form K Crystalline form K was obtained by evaporative crystallization of compound I with acetone at 25° C. dissolved crystalline form A in sufficient acetone at room temperature and allowed the solvent to evaporate at ambient conditions; Crystal form K was obtained. The X-ray powder diffraction pattern of crystal form K is shown in FIG. 11, and the peak list is As shown in Table 9.

[0272] [Table 10]

[0273] Example 8. Preparation of Crystalline Form L Approximately 60 mg of compound I as crystalline form B was dissolved in 4 ml of acetone. Approximately 20 ml of hexane was added to the solution until crystallization of compound I occurred in the form of crystalline form L. The suspension was filtered and the isolated powder was characterized by X-ray powder diffraction. The DSC curve was It shows a broad endotherm at about 65° C., followed by further smaller endothermic and exothermic events. , suggesting that crystalline form L is in fact a solvated form.

[0274] The X-ray powder diffraction pattern of crystalline form L is shown in FIG. 12, and the peak list is shown in Table 11. It is.

[0275] [Table 11]

[0276] Example 9. Solubility of Compound I As noted above, Compound I is barely soluble in a variety of media. The solubility of Compound I in the media is shown in Table 12.

[0277] [Table 12]

[0278] Example 10. Exploratory formulations for stability testing Based on the limited solubility of Compound I in various solvents and water, a suspension was developed for development. Liquid formulations were investigated. The following five formulations were prepared and tested for stability: The compounds were stored in sealed glass vials at room temperature and 40° C. At weeks 6, 8, and 12, The samples were evaluated for I stability.

[0279] [Table 13]

[0280] The formulations prepared in Table 13 were assayed for Compound I as shown in Table 14. The assay was performed using an exploratory UPLC system developed for this purpose.

[0281] [Table 14]

[0282] Results from the study of the stability of Compound I at room temperature and 40° C. are shown in FIG. 14A, respectively. and Figure 14B. In Figure 14A, approximately 70% of the original Compound I was detected at 12 weeks. is a formulation of Compound I as a solution. Formulations having a percentage of Compound I of about 20% of the original at 12 weeks were As can be seen in Figure 1A and Figure 1B, Compound I is a 12 It remains in a stable form in suspension without significant degradation even after weeks. In contrast, the portion of Compound I in the supernatant solution was approximately 20% of the initial amount after 12 weeks at 40°C. Decompose until.

[0283] At the end of the study, compound I was recovered from the four suspensions and confirmed to be in crystalline form by powder X-ray diffraction. The changes in the physicochemical properties of Compound I and the laboratory specimens recovered from the 12-week stability samples were evaluated. The X-ray diffraction pattern of Compound I (control) stored at room temperature is presented in FIG. As shown in FIG. 15, Compound I in each of the four exploratory formulations was incubated at room temperature or 4°C. It retains its polymorphic form even after 12 weeks of storage at 0°C.

[0284] Suspension FID 121744 (shown in Table 17) and 1% tyloxapol The 10% Compound I slurry was subjected to dry heat sterilization at 171° C. for 1 hour. The X-ray diffraction pattern was identical to that of the untreated sample.

[0285] Example 11. Viscosity range finding study of Compound I suspensions Various suspension formulations of Compound I were evaluated for viscosity and precipitation of Compound I. of Carbopol (Carbomer homopolymer type B) and various amounts of sodium chloride. A series of preservative-free Compound I suspensions were prepared. The formulation compositions are shown in Table 15. can be.

[0286] [Table 15]

[0287] The suspensions were visually evaluated for homogeneity. The turbid liquid, FID 121845, was not homogenous and therefore was not further evaluated. Sodium chloride is known to reduce the viscosity of carbomer-containing suspensions, and therefore To this end, sodium chloride was added to the remaining four suspension aliquots in dilutions of 0.2, 0.3 and 1.0 mL. , 0.4 and 0.5% carbomer and 0, 0.05, 0.1, 0.15, 0.2, 0.2 A total of 28 suspensions with concentrations of 5 and 0.3% sodium chloride were obtained.

[0288] The results of the viscosity testing of 28 suspensions are shown in Table 16.

[0289] [Table 16]

[0290] As can be seen in Table 16, the relationship between the amount of carbomer and sodium chloride is of concern. Affects the viscosity of the suspension.

[0291] Further characterization of preservative-free suspensions of Compound I containing Carbopol as a suspending agent. The suspension was prepared for viscosity range finding and sedimentation testing. The compositions, their viscosities and settling times are given in Table 17.

[0292] [Table 17]

[0293] A series of further suspensions are prepared containing a preservative containing hypromellose as a suspending agent; Their viscosities were measured. Sedimentation properties were measured as follows: Well-mixed aliquots were The suspension was filled into a 10 ml glass graduated cylinder. The graduated cylinder was then washed with a polished glass The suspension was sealed with a stopper and parafilm and left to stand at room temperature for 6 months. The composition of 10 ml of suspensions after 6 months, their viscosity and sedimentation were evaluated by visual inspection. Times are shown in Table 18.

[0294] [Table 18]

[0295] Based on the results shown in Tables 9 to 12, the suspensions with or without preservatives were Compound I suspensions having either carbomer or hypromellose as the saturating agent are acceptable. The viscosity and sedimentation properties could be achieved.

[0296] Example 12. pH-dependent stability screening of Compound I suspensions To test the pH stability of Compound I suspensions, the formulations listed in Table 19 below were prepared. All samples contained 0.1% Compound I to ensure consistency of drug concentration. The drug was not soluble in any of the samples, so 0.1% tyloxapol was used as a surfactant. was used as a dispersant to facilitate resuspension of material in the samples. All samples (except the TRIS samples) (a) contains an equivalent amount of phosphate buffer. All samples were placed in 20 mL glass vials. At each assay time point, samples were equilibrated to room temperature and vortexed. The drug was resuspended by mixing and the samples were diluted to concentrations that fell within the linear range of the standard curve.

[0297] [Table 19]

[0298] The amount of compound I in the stability samples was determined using Waters XBridge Shield RP18 column (3.5 μm, 3.0 × 150 mm, 30 °C), mobile phase A 0.1% in water A gradient of 0.1% TFA in TFA and mobile phase B acetonitrile was used, with a 10 μl injection. The volume was analyzed by high performance liquid chromatography (HPMC) at a flow rate of 0.8 ml / min. It was tested on days 0, 4, 7, and 11. In addition, it appeared at a relative retention time (RRT) of 1.23. The major degradants were tracked. The results of the stability study are shown in Table 20.

[0299] [Table 20]

[0300] The major decomposition products shown in Table 20 crystallized and became large as their concentrations increased. It was observed that the formulations shown in Table 21 below formed crystals. were prepared and analyzed for degradant formation.

[0301] [Table 21]

[0302] Data regarding the stability of Compound I in the compositions shown in Table 21 are presented in Table 22 below.

[0303] [Table 22]

[0304] Data on degradant increase are shown in Table 23.

[0305] [Table 23]

[0306] Based on the stability data in the table above, the stability of Compound I is expected to be consistent over the pH range of 5-8. It was concluded that the concentration of compound I in SBE-cyclodextrin varied significantly. The increased solubility of resulted in a decrease in stability.

[0307] Example 13. Stability of 2.5%, 1.5%, 0.5% and 1.5% Ophthalmic Suspensions of Compound I sex Ophthalmic suspensions of Compound I as set forth in Table 29 below, 0.15%, 0.5%, 1. The stability of several lots of 5% and 2.5% (initial pH of 7.34-7.7) has been By periodically monitoring the chemical, physical and microbiological stability characteristics of the product Chemical stability was evaluated by monitoring compound I and its impurities. Physical stability was assessed using pH, osmolality, viscosity, appearance, and X-ray powder diffraction (XRPD). The microbiological stability was evaluated by monitoring the identity and particle size of the samples. The bacteria were monitored by performing a bacterial test. from the stability observation limits (for different lots and various sampling times over the study period). A summary of the results (range: 1-4) is presented in Table 24.

[0308] [Table 24]

[0309] In addition to the above parameters, viscosity was monitored and tested under each storage condition. The viscosity was found to be within 10% of the initial viscosity at each time point. Particle size measurements and sterility were also stable. This was within the observation limit.

[0310] Embodiment 14. Acute toxicity testing of exploratory formulations Four formulations derived from exploratory stability studies in Table 13: FID 121522, FID 121511, FID 121512, and FID 121513 were used as controls for sterile irrigation. The solution was administered five times daily in male New Zealand White rabbits. No toxicity was observed with respect to illumination.

[0311] Embodiment 15. Pharmacokinetic study of exploratory formulations Pharmacokinetic studies were conducted on the same four exploratory formulations provided in Table 13: FID 1 21522, FID 121511, FID 121512, FID 121513 The ocular uptake of Compound I was determined following a single topical bilateral administration in male New Zealand White rabbits. The results are shown in Table 25.

[0312] [Table 25]

[0313] As seen in Table 25, the highest exposure of Compound I was in the cornea, which was approximately 1.5-3 times the levels observed in the conjunctiva, as well as in the aqueous humor and iris-ciliary body. Approximately 10 times the levels observed in human and approximately 10 times the levels observed in plasma. 500 times. C for suspensions containing poloxamer 407 in the cornea max teeth C for two suspensions containing hypromellose maxApproximately twice as much as that for solution formulations C max The C in the cornea of ​​the three suspensions was approximately 38 times higher than that of the control. max teeth, IC of 30 nM 50 The range was approximately 500 to 1200 times that of C min is IC5 The range was approximately 50 to 130 times that of 0.

[0314] Embodiment 16. Pharmacokinetic testing of further formulations Based on results from an exploratory formulation, the chemoattractant effect after a single topical binocular administration in male pigmented rabbits was Additional formulations were prepared to determine additional corneal and aqueous humor concentrations of Compound I. These formulations are shown in Table 26.

[0315] [Table 26]

[0316] The results from the pharmacokinetic study are shown in Table 27.

[0317] [Table 27]

[0318] As shown in Table 27, C for Compound I max and C min Compound I The highest exposure was in the cornea, approximately 3–6 times the level observed in the aqueous humor. The results show that the C max is 0 The concentration was approximately three times that of the 0.05% suspension and approximately 16 times that of the 0.01% suspension. C for 0.5% suspension max is approximately three times that of the 0.05% suspension and 0.01 The C in the cornea of ​​the three suspensions was approximately 9 times that of the % suspension. max is 30 IC in nM 50 The range was approximately 38 to 600 times that of C min is IC 50 Of The range was 0.5 to 7 times.

[0319] Pharmacokinetic studies were performed to determine the efficacy and safety of the formulations FID121746, FID121747, and FID121749 described in Table 26. 45 and FID121744 in the intact eye of male pigmented rabbits. After a single, targeted bilateral dose and with and without a contact lens bandage Corneal and aqueous humor concentrations of Compound I were determined following anterior keratectomy.

[0320] The results from the pharmacokinetic study are shown in Table 28.

[0321] [Table 28]

[0322] Example 17. Toxicity wound healing test using Compound I suspension formulation Toxicity wound healing studies were performed with and without bandage contact lenses. QID topical administration of Compound I after unilateral laser photorefractive keratectomy in rabbits The corneal wound healing was evaluated after targeted bilateral administration of Compound I. The results are listed in Table 29. For comparison, ketorolac tromethamine (ACULAR LS) was The formulations used were cyclosporine (Delta®) and dexamethasone (MAXIDEX®).

[0323] [Table 29]

[0324] The test results were obtained after 3 days at 0.5, 1.5 and 20 mm bandage contact lenses. The mean wound area for corneas treated with 2.5% Compound I suspension and 2.5% Compound I suspension was 1.0 mm in width and 1.5 mm in depth. Corneas treated with ACULAR LS and MAXIDEX using a tact lens, bandage For solvent-treated corneas without a contact lens and for untreated corneas It was demonstrated that the suction pressure was smaller than that of the 0.5, 1.5 and 2.0 mm bandage contact lenses. The mean wound area for corneas treated with 2.5% Compound I suspension was 1.0 mm in diameter and 1.0 mm in length. Corneas treated with solvent using a contact lens and 2 without a bandage contact lens was comparable to that for corneas treated with 0.5% Compound I.

[0325] Example 18. Bacteriostatic / Stability Testing of Exemplary Compound I Suspensions A series of five experimental sterile suspension formulations containing 0.5% Compound I were prepared and Five species of organisms: S. aureus, P. aeruginosa, inosa), E. coli, C. albicans and A. brasiliensis (bacteriostatic / fungistatic effect) The criteria for bacteriostasis were the number of microorganisms (CFU / mL) and the number of bacteria (CFU / mL). All formulations tested demonstrated acceptable levels of bacteriostasis. In addition, the 2.5% Compound I suspension (alternatively FID 121 744) and suspension solvent were also prepared and screened for bacteriostatic / fungistatic activity screening. The bacteriostatic / fungistatic effect was approximately 10 6 of inoculum and / or about 10 5 Inoculum The solution was used and observed for three days.

[0326] All publications and patent documents cited herein are the sole disclosure of the respective patents or publications. Each of the above-mentioned references is incorporated herein by reference in its entirety as if each was specifically and individually indicated to be incorporated by reference. The present invention and its embodiments are described in detail below. However, the scope of the present invention does not include any process, manufacture, It is not intended that any limitation be imposed on any particular embodiment of compositions of matter, compounds, means, methods and / or steps. Various modifications may be made without departing from the spirit and / or essential characteristics of the present invention. Various embodiments, substitutions and variations may be made to the materials disclosed herein. Perform substantially the same function or achieve substantially the same results as the described embodiments; Subsequent modifications, substitutions and / or variations may be made in accordance with such related embodiments of the present invention. It will be readily understood from the present invention that the present invention can be utilized in a variety of ways. The scope of the present invention is defined as any process, manufacture, composition of matter, compound, means, methods and and / or steps are intended to include within their scope modifications, substitutions and variations. The claims are not to be interpreted in any particular order or with any particular elements unless expressly stated to that effect. Various changes in form and detail are within the scope of the appended claims. It should be understood that the present invention may be administered without removal.

Claims

1. Three or more peaks at 2θ values ​​selected from 7.2, 12.7, and 21.4±0.2° 2θ The structure is characterized by an X-ray diffraction pattern having a 【Chemistry 1】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 Crystal form A of (-yl)-benzonitrile (Compound I).

2. 7.2, 12.7, 13.9, 18.1, 21.4, 25.1 and 26.8±0.2° characterized by an X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from The crystalline form A of compound I according to claim 1 .

3. A method for preparing crystalline form A of compound I according to claim 1 or 2, comprising the steps of: and cooling the hot solution of the free base of Compound I to about 0° C. to crystallize Compound I. and crystallizing the compound as Form A.

4. Three or more peaks at 2θ values ​​selected from 7.4, 14.9, and 19.1±0.2° 2θ The structure is characterized by an X-ray diffraction pattern having the formula: 【Chemistry 2】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 Crystal form C of (4-yl)-benzonitrile (Compound I).

5. 7.4、14.1、14.9、16.4、19.1、26.1、31.2±0.2°2 characterized by an X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 5. The crystalline form C of compound I according to claim 4 .

6. A method for preparing crystalline form C of compound I according to claim 4 or 5, comprising the steps of: Compound I in the above is heated to at least about 250° C., or at least about 270° C., or at least about 280° C. The method comprises heating to a temperature.

7. Three or more peaks at 2θ values ​​selected from 12.7, 16.7, and 22.6±0.2° 2θ The structure is characterized by an X-ray diffraction pattern having a 【Chemistry 3】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 Crystal form E of (4-yl)-benzonitrile (Compound I).

8. 12.7、15.1、16.7、22.6、27.1、27.7、28.5±0.2° characterized by an X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 8. The crystalline form E of compound I according to claim 7 .

9. A method for preparing crystalline form E of compound I according to claim 7 or 8, comprising the steps of: The solvate form is heated to a temperature greater than about 250° C. or about 260° C. to convert compound I to crystalline form E.

4. A method comprising:

10. structure 【Chemistry 4】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 -yl)-benzonitrile (Compound I) crystalline hydrate.

11. Three or more peaks at 2θ values ​​selected from 6.6, 14.4, and 18.3±0.2° 2θ The crystal of compound I according to claim 10, characterized by an X-ray diffraction pattern having the formula: Hydrate.

12. 6.6、11.9、14.4、18.3、23.9、26.5、29.2±0.2°2 characterized by an X-ray diffraction pattern having three or more peaks at 2θ values ​​selected from 11. The crystalline hydrate of Compound I according to claim 10.

13. A process for preparing the crystalline hydrate of compound I according to any one of claims 10 to 12. and equilibrating a slurry of Compound I in a mixture of water and a water-miscible solvent to obtain Compound I. crystallizing the compound as a crystalline hydrate.

14. The method of claim 13, wherein the water-miscible solvent is acetone.

15. The equilibration may be for about 12 hours, about 18 hours, or about 24 hours, or about 48 hours. The method of claim 13, wherein

16. structure 【Chemistry 5】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 A crystalline methanol solvate of (methyl-yl)-benzonitrile (Compound I).

17. 6. Three or more peaks at 2θ values ​​selected from 1, 14.5, and 22.7±0.2° 2θ 17. The crystal of compound I according to claim 16, characterized by an X-ray diffraction pattern having the formula: Solvate of methanol.

18. Select from 6.1, 12.2, 14.5, 18.0, 22.7, 24.6±0.2°2θ The method is characterized by an X-ray diffraction pattern having three or more peaks at 2θ values ​​corresponding to the above-mentioned values.

17. The crystalline methanol solvate of compound I according to claim 16.

19. A crystalline methanol solvate of compound I according to any one of claims 16 to 18 is prepared. A method for preparing a polymorphic form of Compound I by equilibrating a slurry of Compound I in methanol. and providing compound I as said crystalline methanol solvate. 。

20. 20. The method of claim 19, wherein the equilibration is carried out at room temperature for at least about 24 hours. How to.

21. structure 【Chemistry 6】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 A crystalline acetonitrile solvate (Form J) of (-yl)-benzonitrile (Compound I).

22. Three or more peaks at 2θ values ​​selected from 8.2, 17.0, and 23.8±0.2° 2θ 22. The crystal of compound I according to claim 21, characterized by an X-ray diffraction pattern having the formula: Soluble acetonitrile.

23. Select from 8.2, 11.8, 17.0, 22.8, 23.8, 27.6±0.2°2θ The method is characterized by an X-ray diffraction pattern having three or more peaks at 2θ values ​​corresponding to the above-mentioned values.

22. A crystalline acetonitrile solvate of compound I according to claim 21.

24. A crystalline acetonitrile solvate of compound I according to any one of claims 21 to 23. A method for preparing Compound I by equilibrating a slurry of Compound I in acetonitrile as said crystalline acetonitrile solvate.

25. 25. The method of claim 24, wherein the equilibration is carried out at room temperature for at least about 24 hours. How to.

26. Three or more peaks at 2θ values ​​selected from 5.3, 12.3, and 22.4±0.2° 2θ The structure is characterized by an X-ray diffraction pattern having the formula: 【Chemistry 7】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 Crystal form K of (-yl)-benzonitrile (Compound I).

27. 5.3, 6.5, 10.5, 12.3, 17.2, 19.3, 22.4±0.2°2θ The X-ray diffraction pattern is characterized by having three or more peaks at 2θ values ​​selected from 27. The crystalline form K of compound I according to claim 26.

28. 28. A method for preparing crystalline form K of compound I according to claim 26 or 27, comprising the steps of: and crystallizing the compound I in a crystalline form K by evaporation of the solution of the compound I in the crystalline form K. and

29. Three or more peaks at 2θ values ​​selected from 7.1, 8.7, and 10.6±0.2° 2θ Characterized by an X-ray diffraction pattern having the structure 【Chemistry 8】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 Crystal form L of (-yl)-benzonitrile (Compound I).

30. 3.5, 7.1, 8.7, 10.6, 12.2, 19.1, 22.4±0.2°2θ The X-ray diffraction pattern is characterized by having three or more peaks at 2θ values ​​selected from the group consisting of 30. The crystalline form L of compound I according to claim 29,

31. A method for preparing crystalline form L of compound I according to claim 29 or 30, comprising the steps of: adding a solvent to a solution of Compound I in acetone to provide Compound I as crystalline form L; The method includes:

32. 32. The method of claim 31 , wherein the hydrocarbon solvent is hexane.

33. An effective amount of crystalline form A, crystalline form C, crystalline form D, crystalline form E, crystalline form F, crystalline form H, crystalline form I, Crystal form D, crystalline form E, crystalline form F, crystalline form L, crystalline form K, and combinations thereof. The crystalline form of compound I according to any one of claims 1 to 32, which is selected from the group consisting of crystalline forms of compound I, crystalline forms of compound I according to any one of claims 1 to 32, and crystalline forms of compound I according to any one of claims 1 to 32, which are selected from the group consisting of crystalline forms of compound I, crystalline forms of compound I according to any one of claims 1 to 32, and an excipient capable of administering the pharmaceutical preparation.

34. 34. The pharmaceutical formulation of claim 33, comprising said crystalline form A in substantially pure form.

35. 34. The pharmaceutical formulation of claim 33, comprising the crystalline form C in substantially pure form.

36. 34. The pharmaceutical formulation of claim 33, comprising the crystalline form E in substantially pure form.

37. 34. The pharmaceutical formulation of claim 33, comprising the crystalline form F in substantially pure form.

38. 34. The pharmaceutical formulation of claim 33, comprising the crystalline form K in substantially pure form.

39. 34. The pharmaceutical formulation of claim 33, comprising the crystalline form L in substantially pure form.

40. 34. The pharmaceutical formulation of claim 33, comprising a mixture of two or more crystalline forms of Compound I.

41. Crystalline forms B and E, Crystalline forms B and F, Crystalline forms B and C, Crystalline forms A and C, Crystalline forms 41. The medicament of claim 40, comprising a mixture of forms A and F in a ratio of about 1:99 to about 99:

1. formulation.

42. A pharmaceutical preparation according to any one of claims 33 to 41 which is formulated for ophthalmic use.

43. 1. An aqueous formulation comprising: 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl) - benzonitrile (compound I) or a salt, co-crystal or polymorph thereof, and A surfactant, a suspending agent, an osmotic agent, a buffer, a preservative, a salt, and a preservative are selected from the group consisting of An aqueous formulation comprising one or more excipients.

44. The 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3- In the formulation, 44. The aqueous formulation of claim 43, which is present as a suspension at

45. The 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3- yl)-benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof, 45. The method of claim 43 or 44, wherein the composition is present in the formulation in an amount of from about 3.5% w / v to about 3.5% w / v. The aqueous formulation described above.

46. 4-(7-hydroxy-2-isopropyl) propyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or its salts, co-crystals or polymorphs, Surfactants, Suspension agents, and one or more excipients selected from the group consisting of osmotic agents, buffers, preservatives, salts and preservatives; 46. ​​The aqueous formulation according to any one of claims 43 to 45, comprising

47. It is present as a suspension in the formulation in an amount of about 0.5% w / v to about 3.5% w / v. 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl )-benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof; Nonionic surfactants; Suspension agents; Osmotic agents; Buffer; salt; and 47. The formulation according to any one of claims 43 to 46, optionally comprising a preservative.

48. 4-(7-hydroxy-2-isopropyl) propyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (Compound I) or Suspensions of their salts, co-crystals or polymorphs; Nonionic surfactants; Suspension agents; Osmotic agents; Buffer; Optionally, salt; Optionally, a preservative; and Formulations containing sufficient quantity (qs) of water to reach 100%.

49. The non-ionic surfactant may be a polysorbate surfactant, a block copolymer of ethylene oxide, Poly(propylene oxide) surfactants, poloxamers, tyloxapol and their combinations The formulation of any one of claims 43 to 48, wherein the formulation is selected from the group consisting of:

50. The non-ionic surfactant may be at least about 0.001% w / v, at least about 0.0 1% w / v, at least about 0.02% w / v, at least about 0.03% w / v or less Both are about 0.04% w / v, and are not more than about 1% w / v, not more than about 0.5% w / v, not more than about 0. 3% w / v or less, or about 0.2% w / v or less, about 0.1% w / v or less, or about 0.08% w / v or less 50. The formulation of claim 49, wherein tyloxapol is present in an amount of no more than v.

51. 51. The formulation of claim 50, comprising tyloxapol in an amount of about 0.05% w / v.

52. The non-ionic surfactant is in an amount of about 15% to about 20% w / v of the formulation. The formulation of any one of claims 43 to 49, which is a poloxamer.

53. The suspending agent is carbomer, hydroxypropyl methylcellulose (hypromellose) , polyethylene glycol, and combinations thereof. The formulation according to any one of claims 1 to 5.

54. The suspending agent may be at least about 0.05% w / v, at least about 0.1% w / v or less at most about 0.2% w / v, and not more than about 1.0% w / v, not more than about 0.6% w / v, or 53. A carbomer present in the formulation in an amount of about 0.5% w / v or less. The formulation described in

55. The carbomer is in an amount of 0.1% w / v to about 0.3% w / v or about 0.2% w / v.

55. The formulation of claim 54, wherein the formulation is present in the formulation at

56. The suspending agent may be at least about 0.05% w / v, at least about 0.1% w / v or less at least about 0.25% w / v, and less than about 1.8% w / v, less than about 1.0% w / v, Hydride present in the formulation in an amount of less than about 0.8% w / v or less than about 0.6% w / v.

54. The formulation of claim 53, wherein the active ingredient is propyl methylcellulose.

57. The suspending agent is a polyethylene glycol having a molecular weight of about 200 Da to about 20,000 Da.

54. The formulation of claim 53, wherein the PEG-coated polysaccharide is cholesteryl (PEG).

58. The suspending agent may be from about 4% w / v to about 9% w / v, from about 5% w / v to about 8% w / v or PEG 400 at a concentration of about 7% w / v or about 1% w / v to about 4% w / v, about 1% w / v to about 3% w / v 58. The formulation of claim 57, wherein the PEG 6000 is at a concentration of about 2% w / v or about 2% w / v. 。

59. Claims 43 to 55, wherein the suspending agent is substantially all carbomer homopolymer type B. The formulation according to any one of claims 1 to 5.

60. 60. The method of claim 43, wherein the osmotic agent is selected from the group consisting of polyols. The formulation according to claim 1.

61. The polyols include mannitol, glycerin, xylitol, sorbitol and proline.

61. The method of claim 60, wherein the amine is selected from the group selected from pyrene glycol, and combinations thereof. Formulation.

62. The polyol may be from about 0.05% w / v to about 10% w / v, from about 0.1% w / v to about 8% in an amount of about 0.1% w / v to about 7% w / v, about 0.1% w / v to about 5% w / v 62. The formulation of claim 61, wherein

63. The polyol may be from about 0.1% w / v to about 5% w / v, or about 0.2% w / v, about 0.3% w / v, about 0.4% w / v, about 0.5% w / v, about 1% w / v, about 2% w / v, about 2.5 %w / v, about 3.0%w / v, about 3.5%w / v, about 4.0%w / v, about 4.5%w / v or mannitol or glycerin, present in the formulation in an amount of about 5% w / v.

63. The formulation of claim 62.

64. The buffer solution may be selected from the group consisting of acetate, ascorbate, borate, bicarbonate, carbonate, citrate, etc. Salt, edetate (EDTA) gluconate, lactate, phosphate, propionate and TR IS (tromethamine), The formulation described above.

65. 65. The formulation of claim 64, wherein the buffer is phosphate or TRIS.

66. 66. The formulation of any one of claims 43 to 65, wherein the salt is sodium chloride.

67. The suspending agent is Carbopol (Carbomer homopolymer type B) and sodium chloride. The amount of um is about 2 when using spindle CP-42 at 60 rpm at about 25°C.

67. The composition of claim 66, wherein the amount of the active ingredient is adjusted to provide a viscosity of the formulation of from 0 cP to about 200 cP. formulation.

68. The sodium chloride may be about 0.01% w / v to about 0.5% w / v, about 0.02% w / v ~about 0.4%w / v, about 0.03%w / v~about 0.3%w / v, about 0.04%w / v~about In an amount of about 0.2% w / v, about 0.05% w / v to about 0.1% w / v or about 0.05% w / v 67. The formulation of claim 66, wherein the formulation is present in a

69. 69. The method according to claim 48, wherein the pH of the formulation is from about 5.5 to about 8.

0. The formulation described above.

70. 70. The method of claim 69, wherein the pH of the formulation is about 6.0 to about 8.0, about 6.0, or about 7.

4. The formulation described.

71. At least about 1.5 w / v%, at least about 3.0 w / v%, at least about 3.5 w / v% % or at least about 4.5 w / v%, but not more than about 10.0 w / v%, about 8.0 w / v% cyclodextrin in an amount of about 6.5 w / v% or less, about 6.5 w / v% or less, or about 5.5 w / v% or less 71. Any one of claims 48 to 70, further comprising an additional agent selected from the group consisting of phosphorus The formulation described in item .

72. The cyclodextrin may be hydroxypropyl in an amount of about 5% w / v of the formulation. β-cyclodextrin or sulfoalkyl ether β-cyclodextrin. The formulation of claim 71.

73. The compound I or a salt, co-crystal, or polymorph thereof is present in an amount of about 0.5% w / v to about 2.5% w / v. / v, The non-ionic surfactant may be tyloxane in an amount of about 0.01% to 0.2% w / v. sapol, poloxamer or a combination thereof; The suspending agent is hydroxypropyl methylcellulose, polyethylene glycol or carbamide. Bomer homopolymer type B; The osmotic agent comprises at least one polysaccharide in an amount of about 0.05% w / v to about 10% w / v. is a liore; the buffer is edetate, phosphate, borate or a combination thereof; Salt; and Contains up to 100% qs of water; and 49. The formulation of claim 48, wherein the pH ranges from about 5.5 to about 8.

0.

74. The compound I or a salt, co-crystal, or polymorph thereof is present in an amount of about 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2.5% w / v; The non-ionic surfactant is in an amount of about 0.04% w / v to about 0.06% w / v. loxapol, poloxamer in an amount of about 0.005% to 0.12% w / v, or The combination is: The suspending agent may be hydroxypropyl methylcellulose in an amount of about 0.1% to about 0.8% w / v. cellulose, polyethylene glycol in an amount of about 2% w / v to about 8% w / v, Carbomer homopolymer type B or its equivalent in an amount of 0.05% w / v to about 0.5% w / v A combination of: The osmotic agent may be mannitol or glycerol in an amount of about 0.1% w / v to about 5% w / v. is phosphorus; the buffer is edetate, phosphate, borate, tromethamine or a combination thereof; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; and Contains up to 100% qs of water; and The process according to any one of claims 48 to 73, wherein the pH ranges from about 5.5 to about 8.

0. Agent.

75. About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2 4-(7-hydroxy-2-isopropyl-4-oxo-4H in an amount of 5% w / v -quinazolin-3-yl)-benzonitrile (Compound I) or a salt thereof, co-crystal or poly Suspension of forms, Tyloxapol in an amount of about 0.04% to about 0.06% w / v; Carbomer homopolymer type B in an amount of about 0.05% w / v to about 0.4% w / v; Glycerin in an amount of about 0.5% to about 5% w / v; Selected from the group consisting of edetate, phosphate, borate, tromethamine and combinations thereof. a buffer solution; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; and Contains up to 100% qs water, The formulation has a pH in the range of about 5.5 to about 8.

0.

76. The formulation of any one of claims 43 to 75, wherein compound I is polymorphic form B.

77. About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2 4-(7-hydroxy-2-isopropyl-4-oxo-4H in an amount of 5% w / v a suspension of polymorphic form B of (-quinazolin-3-yl)-benzonitrile (Compound I); Tyloxapol in an amount of about 0.04% to about 0.06% w / v; Carbomer homopolymer type B in an amount of about 0.05% w / v to about 0.4% w / v; Glycerin in an amount of about 0.5% to about 5% w / v; a buffer selected from edetate, phosphate, borate, tromethamine or combinations thereof; Sodium chloride in an amount of 0.01% w / v to about 1% w / v; and A formulation containing up to 100% qs water, The formulation has a pH in the range of about 5.5 to about 8.

0.

78. About 0.5% w / v, about 1.0% w / v, about 1.5% w / v, about 2.0% w / v or about 2 Compound I in an amount of 5% w / v; About 0.05% w / v tyloxapol; Carbomer homopolymer type B at about 0.2% w / v; About 2.0% glycerin; Tromethamine buffer; and Hydrochloric acid to adjust the pH to about 6.4 to about 8.4; About 0.05% w / v sodium chloride; and Contains up to 100% qs water, 78. The formulation of claim 77, which is free of preservatives.

79. The polymorphic form B has a 2θ angle selected from 9.3, 10.6 and 14.4±0.2 degrees 2θ.

77. The method of claim 76, characterized by an X-ray diffraction pattern having three or more peaks at values 80. The formulation according to any one of claims 1 to 79.

80. Using spindle CP-42 at either 3 rpm or 60 rpm at approximately 25°C. Any of claims 43 to 79, having a viscosity of about 20 cP to about 200 cP when measured by a 300 psi (100 psi) measuring instrument. The formulation according to any one of claims 1 to 5.

81. A weight average molecular weight of about 200 to about 450 milliosmoles per kilogram (mOsm / kg) 81. The formulation of any one of claims 43 to 80, having a molar concentration.

82. After 6 months of storage at room temperature, the 82. The composition of claim 43, which exhibits less than 5%, less than about 4%, less than about 3%, or less than about 2% precipitation. The formulation according to any one of claims 1 to 4.

83. The amount of Compound I in the formulation was approximately 6 months, approximately 8 months, approximately 10 months, and approximately 20 months after storage under refrigeration. At least 90% of the initial amount after about 12 months, about 15 months, or about 18 months The formulation according to any one of claims 43 to 82, wherein

84. The amount of Compound I in the formulation decreased slightly from the original amount after about 18 months of storage under refrigeration. at least about 91%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least 96%, at least about 97%, or at least about 98% The formulation according to any one of claims 43 to 83.

85. Contains less than about 10% decomposition products after 6 months under refrigeration, said decomposition products being less than 0.1% by HPMC using a gradient of trifluoroacetic acid (TFA) water / acetonitrile mobile phase.

43. The compound according to claim 43, wherein the compound has a relative retention time of 1.23 compared to compound I when analyzed by 85. The formulation according to any one of claims 1 to 84.

86. About 10% or less of Compound I in the formulation decomposes upon storage at 40° C. for 12 weeks. The formulation according to any one of claims 43 to 85.

87. The compound I may be of crystalline form A, crystalline form B, crystalline form C, crystalline form E, crystalline form F, crystalline form G, crystalline form J, crystalline form K, crystalline form L, and combinations thereof. The formulation of any one of claims 43 to 86, wherein the formulation is in a crystalline form.

88. The compound I may be of crystalline form A, crystalline form B, crystalline form C, crystalline form E, crystalline form F, crystalline form selected from the group consisting of crystalline form K, crystalline form L and combinations thereof. 43-86. The formulation according to any one of claims 43 to 86.

89. A quantity of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline 3-yl)-benzonitrile (Compound I) or a salt, co-crystal or polymorph thereof; Nonionic surfactants; Suspension agents; Osmotic agents; Buffer; salt; Optionally, a preservative; and Mixing water up to 100% qs; and A method of making the formulation comprising adjusting the pH to a range of about 5.5 to about 8.

0.

90. 90. The method of claim 89, wherein said Compound I is added as a stock suspension.

91. 89 or 9. The stock suspension is milled to obtain a desired particle size of Compound I. The method according to claim 0.

92. A method for treating ocular surface pain in a subject in need thereof, comprising administering to said subject an effective amount of a compound comprising Construction: 【Chemistry 9】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 -yl)-benzonitrile (compound of formula I) or a salt, solvate, polymorph or copolymer thereof instilling the crystals into the subject.

93. 93. The method of claim 92, wherein the ocular surface pain is chronic ocular surface pain.

94. 93. The method of claim 92, wherein the compound of formula I is administered to the cornea of ​​the subject.

95. Any one of claims 92 to 94, wherein the COSP is associated with dry eye disease. The method described above.

96. 96. The method of claim 95, wherein said administering results in a reduction in symptoms of dry eye disease.

97. 96. The method of claim 95, wherein said administering results in a reduction in said pain associated with dry eye disease. Law.

98. The administration may be effective to relieve symptoms such as dry eyes, eye discomfort, eye redness, eye burning or stinging, grittiness or or foreign body sensation or photophobia by at least about 10%.

97. The method of claim 96.

99. The subject is a patient suffering from dry eye disease, Sjogren's syndrome, conjunctivitis (keratoconjunctivitis, vernal keratoconjunctivitis) , allergic conjunctivitis), corneal epithelial basement membrane dystrophy, Acanthamoeba, Streptococcus aureus Fibromyalgia, Meibomian gland dysfunction, Thyroid eye disease, Rosacea, Ptosis, Keratoconus, Ocular pain syndrome group, Stevens-Johnson syndrome, corneal epitheliopathy, corneal neuropathy (LASIK-induced corneal neuropathy), corneal dystrophies (including recurrent corneal dystrophies), epithelial Basement membrane dystrophy, corneal erosion or corneal abrasion (recurrent corneal erosion or corneal (including abrasions), ocular surface disease, blepharitis, graft-versus-host disease, meibomianitis, glaucoma, conjunctival Keratopathy (herpetic keratopathy, filamentous keratopathy, band or bullous keratopathy, lagophthalmos keratopathy) keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery , Multiple Sclerosis, Trichiasis, Pterygium, Neuralgia, Xerophthalmia, Neurotrophic Keratitis Patients undergoing photorefractive keratectomy (PRK) or laser corneal ablation surgery One or more of the following eye pain symptoms persisting for at least 3 months after LASIK surgery: The method according to any one of claims 92 to 98, wherein the patient is suffering from a disease.

100. 100. The method of claim 92, further comprising administering to the subject an additional therapeutic agent. The method according to claim 5.

101. The administration may provide a decrease in serotonin levels by at least about 3, at least about 4, or at least about 5% compared to placebo. , at least about 6, at least about 7, at least about 8, at least about 9, or at least about Claims 92-100, resulting in a reduction in pain score on the visual acuity scale (VAS) of 10.

2. The method according to claim 1 .

102. The reduction in VAS score is a decrease in VAS score before and after administration of Compound I to the subject. The method of claim 101, resulting from a difference in

103. The reduction in VAS score occurs within about half an hour after administration of Compound I to the subject. The method of claim 101 or 102.

104. The administration may provide a response of at least about 1, at least about 2, or both on the McMonnies scale. , at least about 3, at least about 4, or at least about 5, The method of any one of claims 92 to 104, wherein

105. The treatment was associated with improved best corrected visual acuity, intraocular pressure, slit lamp biomicroscopy, and diffuse stimuli compared to placebo. No changes in pupil examination, blink rate, tear production, or corneal staining. The method according to any one of claims 92 to 104.

106. The compound of formula I is administered in the form of a formulation according to any one of claims 43 to 86. The method according to any one of claims 92 to 106,

107. The formulation is administered for at least about one month, about two months, or about three months. The method of claim 106.

108. 107. The method of claim 106, wherein the formulation is administered 1 to 4 times daily.

109. A formulation according to any one of claims 1 to 86 for use in the treatment of ocular surface pain. 。

110. The ocular surface pain has been present for at least 1 month, at least 2 months, or at least 3 months.

110. The formulation for use according to claim 109, wherein the pain is chronic ocular surface pain that persists for a period of time.

111. 1. A method of reducing ocular surface pain in a subject in need thereof, comprising administering to a subject a compound of the structure: 【Chemistry 10】 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazoline-3 3. The method of claim 1, wherein the compound is selected from the group consisting of (1-methyl-1-yl)-benzonitrile (formula I) and salts, solvates, polymorphs, and co-crystals thereof. administering instillation to a subject.

112. 112. The method of claim 111, wherein the ocular surface pain is chronic ocular surface pain (COSP).

113. 113. The method of claim 111 or 112, wherein the COSP is associated with dry eye disease. method.

114. 112. The method of claim 111, wherein said administration results in a reduction in symptoms of dry eye disease.

115. 113. The method of claim 113, wherein the administration results in a reduction in the pain associated with dry eye disease. method.

116. The administration may be effective to relieve symptoms such as dry eyes, eye discomfort, eye redness, eye burning or stinging, grittiness or or foreign body sensation or photophobia by at least about 10%. The method of claim 115.

117. The subject is a patient suffering from dry eye disease, Sjogren's syndrome, conjunctivitis (keratoconjunctivitis, vernal keratoconjunctivitis) , allergic conjunctivitis), corneal epithelial basement membrane dystrophy, Acanthamoeba, Streptococcus aureus Fibromyalgia, Meibomian gland dysfunction, Thyroid eye disease, Rosacea, Ptosis, Keratoconus, Ocular pain syndrome group, Stevens-Johnson syndrome, corneal epitheliopathy, corneal neuropathy (LASIK-induced corneal neuropathy), corneal dystrophies (including recurrent corneal dystrophies), epithelial Basement membrane dystrophy, corneal erosion or corneal abrasion (recurrent corneal erosion or corneal (including abrasions), ocular surface disease, blepharitis, graft-versus-host disease, meibomianitis, glaucoma, conjunctival Keratopathy (herpetic keratopathy, filamentous keratopathy, strip-shaped or bullous keratopathy, lagophthalmos keratopathy) keratitis (including herpes simplex virus keratitis), iritis, episcleritis, corneal surgery, Recovered from multiple sclerosis, trichiasis, pterygium, neuralgia, xerophthalmia, and neurotrophic keratitis. Patients undergoing photorefractive keratectomy (PRK) or laser keratomileusis surgery One or more persistent eye pain symptoms after LASIK surgery for at least 3 months The method according to any one of claims 111 to 116, wherein the patient is suffering from.

118. Any of claims 111 to 117, further comprising administering an additional therapeutic agent to the subject.

3. The method according to claim 1 .

119. The administration may provide a decrease in serotonin levels by at least about 3, at least about 4, or at least about 5% compared to placebo. , at least about 6, at least about 7, at least about 8, at least about 9, or at least about 10. A reduction in pain score on the visual acuity scale (VAS) of 111 to 11.

9. The method according to any one of claims 8 to 9.

120. The administration may provide a 5-fold increase in serotonin levels, such as at least about 6, at least about 7, or at least about 8% compared to placebo. , resulting in a reduction in VAS pain score of at least about 9 or at least about 10.

120. The method of any one of claims 11 to 119.

121. The reduction in VAS score is determined by comparing the VAS scores before and after administration of Compound I to the subject. The method of claim 119 or 120, resulting from the difference between a and b.

122. The administration may provide a response of at least about 1, at least about 2, or both on the McMonnies scale. , at least about 3, at least about 4, or at least about 5, The method according to any one of claims 111 to 121, wherein

123. The administration results in an improvement in visual acuity score of at least about 3 compared to a VAS score prior to administration of the compound. The method of claim 119, which results in a reduction in pain score on a visual analog scale (VAS).

124. The compound of formula I is administered in the form of a formulation according to any one of claims 1 to 86. The method according to any one of claims 111 to 123.

125. 1. A method of treating or reducing ocular surface pain in a subject in need thereof, comprising administering to a subject a compound of the structure: 【Chemistry 11】 The compound 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolidinyl) The method includes administering to the subject a formulation comprising (a) benzonitrile (compound I) fruit, The formulation provided a rabbit corneal Cmax of Compound I that was about 1.5 to about 3 times the conjunctival Cmax. and Cmax is the maximum concentration of Compound I in a particular tissue after administration of a single dose. method.

126. The compound I is administered in a formulation according to any one of claims 48 to 86. The method of claim 125.

127. A method for treating or reducing ocular surface pain in a subject in need thereof, comprising the structure : 【Chemistry 12】 The compound 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolidinyl) The method includes administering to the subject a formulation comprising (a) benzonitrile (compound I) fruit, The formulation exhibited a Cmax of Compound I in rabbit corneas that was approximately 500 times that of Compound I in plasma. Cmax of Compound I in a particular tissue after administration of a single dose The method according to claim 1, wherein the maximum concentration of

128. The compound I is administered in a formulation according to any one of claims 48 to 86. The method of claim 127.

Citation Information

Patent Citations

  • Quinazolinone derivatives useful as vanilloid antagonists

    JP2012515150A